When the disease process is confined to a mass lesion with no or minimal evidence of blood and less than 25% marrow involvement, the diagnosis is lymphoblastic lymphoma; with blood and greater than 25% marrow involvement, ALL is the appropriate term.
| Excerpt | Reference |
|---|
| "Twelve adult patients with non-leukaemic lymphoblastic lymphoma were treated with combination chemotherapy and central nervous system prophylaxis according to the protocol developed at Stanford University." | ( Mead, GM; Sweetenham, JW; Whitehouse, JM, 1992) |
| "45 cases of acute lymphocytic leukemia (ALL) were treated with vincristine, daunorubicin, cyclophosphamide, prednisone with a CR rate of 88." | ( , 1992) |
| "Twenty-seven children with acute lymphoblastic leukemia (ALL) were studied by magnetic resonance (MR) imaging after central nervous system (CNS) treatment." | ( Laitinen, J; Lanning, M; Pääkkö, E; Pyhtinen, J; Vainionpää, L, 1992) |
| "One twin had been diagnosed with acute lymphoblastic leukemia and given prophylactic treatment involving intrathecal methotrexate." | ( Berry, DH; Caldwell, D; Spence, GT; Williams, J; Zolten, AJ, 1992) |
| "We enrolled children with acute lymphoblastic leukemia (ALL) in a Pediatric Oncology Group (POG) pilot study to monitor erythrocyte (RBC) methotrexate (MTX) and folate (F) levels before and during treatment." | ( Cheo, DL; Graham, ML; Harrison, MP; Kamen, BA; Leventhal, BG; Pullen, DJ; Shuster, JJ; Whitehead, VM, 1992) |
| "Therapy for acute lymphocytic leukemia includes induction, consolidation, maintenance, and CNS prophylaxis." | ( McCauley, DL, 1992) |
| "Of the 21 adolescent patients with acute lymphoblastic leukemia or Hodgkin disease who were to take prednisone as outpatients, 11 patients were found to be nonadherent to treatment (52%)." | ( Chasalow, F; Festa, RS; Lanzkowsky, P; Tamaroff, MH, 1992) |
| "We treated 31 children with acute lymphoblastic leukemia (ALL), 14 children with acute nonlymphoblastic leukemia (ANLL) in relapse, and 1 child with chronic myelogenous leukemia (CML) in blast crisis (CALLA negative) with indicine N-oxide in a Phase II study." | ( Davis, D; Hammond, GD; Hughes, CH; Krailo, MD; Krivit, W; Miser, JS; Smithson, WA, 1992) |
| "In 83 children with untreated acute lymphoblastic leukemia (ALL), we determined the prognostic value of HGPRT activity and the relation between HGPRT activity and resistance to thiopurines." | ( Hählen, K; Huismans, DR; Loonen, AH; Peters, GJ; Pieters, R; van der Does-van den Berg, A; van Wering, ER; Veerman, AJ, 1992) |
| "The case histories of two patients with acute lymphocytic leukemia, who developed central nervous system complication during combined chemotherapy are described." | ( Grexa, E; Kajtár, P; Kardos, M, 1992) |
| "Among the 40 children treated for acute lymphoblastic leukemia (ALL), all of whom had received prior therapy with oral 6MP, 1 complete and 1 partial response were achieved." | ( Adamson, PC; Balis, F; Gillespie, A; Kamen, BA; Poplack, DG; Ragab, AH; Steinberg, SM; Vietti, TJ; Zimm, S, 1992) |
| "More effective treatment for adult lymphoblastic lymphoma is required." | ( Chan, TK; Chiu, E; Ho, FC; Liang, R; Lie, A; Loke, SL; Todd, D, 1991) |
| "Twenty-nine adult patients with acute lymphocytic leukemia (ALL) were treated with combination chemotherapy consisting of behenoyl-ara-C, adriamycin, cyclophosphamide, vindesine and prednisolone (BHAC-ACVP regimen)." | ( Horiuchi, A; Kageyama, T; Kakishita, E; Kanamaru, A; Kawagoe, H; Kitani, T; Masaoka, T; Nagai, K; Tatsumi, N; Yasunaga, K, 1992) |
| "Thirty-four adults with refractory acute lymphocytic leukemia received salvage therapy with mitoxantrone 5 mg/m2 intravenously over 1 hour daily for 5 days and cytosine arabinoside (ara-C) 3 g/m2 intravenously over 2 hours every 12 hours for six doses, followed by granulocyte-macrophage colony-stimulating factor (GM-CSF) 125 microgram/m2 intravenously over 4 hours daily until recovery of granulocytes above 2." | ( Anaissie, E; Beran, M; Estey, EH; Gutterman, J; Kantarjian, HM; Keating, MJ; O'Brien, S; Rios, MB, 1992) |
| "Thirty children with refractory acute lymphocytic leukemia (ALL) were treated with mitoxantrone, 8 mg/m2/day, for 5 days." | ( Estrada, J; Graham, ML; Ragab, AH; Rosen, D; Starling, KA; Wilkenson, RW; Wilkerson, RW, 1991) |
| "Of 2947 children with acute lymphocytic leukemia (ALL), treated during three consecutive studies of the Pediatric Oncology Group (1974-1986), 52 (1." | ( Abdel-Mageed, A; Borowitz, M; Boyett, J; Crist, WM; Frankel, LS; Pullen, J; Ragab, AH; Shuster, JJ; Sullivan, MP; van Eys, J, 1991) |
| "Current medical treatments for childhood acute lymphoblastic leukemia (ALL) have improved the outlook to where more than 50% can be expected to survive five years or more." | ( Hammond, GD; Kaleita, TA; MacLean, WE; Noll, RB; O'Brien, RT; Stehbens, JA; Waskerwitz, MJ, 1991) |
| "A 52-year-old female patient treated for acute lymphoblastic leukemia with combination chemotherapy (cyclophosphamide, vincristine, adriamycin and prednisone), broad spectrum antibiotics and amphotericin via a Hickman catheter placed in the superior vena cava, developed echocardiographically confirmed tricuspid regurgitation." | ( Marshall, TM; Pollick, C; Shepherd, JD; Tirgan, MH, 1991) |
| "Of 125 children with acute lymphoblastic leukemia (ALL), who had been in continuous remission for three years on chemotherapy, 108 patients received biological response modifiers (BRM) such as Bestatin, N-CWS, OK-432 and/or PSK in order to prevent relapse after treatment suspension." | ( Kawa, K; Konishi, S; Mabuchi, S; Tsujino, G, 1991) |
| "The patient, an 18-year-old man with acute lymphocytic leukemia, was given high-dose carboplatin as a part of a phase I trial of this agent for the treatment of leukemia." | ( Boitnott, JK; Fleisher, M; Hruban, RH; Menendez-Botet, C; Meyers, P; Sternberg, SS, 1991) |
| "Three children with acute lymphocytic leukemia (ALL) developed delayed-onset transient hemiparesis and facial palsy after intrathecal (IT) administration of methotrexate (MTX) alone or as part of triple intrathecal chemotherapy for central nervous system (CNS) prophylaxis." | ( Mahoney, DH; Oshman, DG; Yim, YS, 1991) |
| "Ten patients age 13-52 years with acute lymphoblastic leukemia (ALL) in first complete remission (CR) (1), second CR (6), or relapse (3) were treated with cyclophosphamide 50 mg/kg daily x 4 and total body irradiation 3 Gy daily x 4 followed by infusion of autologous marrow purged with 4-hydroperoxycyclophosphamide (4-HC) at 100-120 micrograms/ml." | ( Bloom, EJ; Borochovitz, D; Colvin, OM; Gonzales-Chambers, R; Mangan, KF; Przepiorka, D; Rosenfeld, CS; Shadduck, RK, 1991) |
| "A 15-y-o girl who had relapsed acute lymphoblastic leukemia, followed by the two-years complete remission, was treated with a reinduction chemotherapy including methotrexate, vincristine, L-asparaginase and dexamethasone (MOAD)." | ( Inoue, N; Kakishita, E; Kanemaru, A; Kohsaki, M; Konya, H; Miyazaki, E; Okamoto, T; Takemoto, Y; Tamura, S, 1991) |
| "A total of 62 patients with high-risk acute lymphoblastic leukemia (ALL) were treated with fractionated total body irradiation, high-dose cytosine arabinoside and melphalan followed by bone marrow transplantation (BMT)." | ( Benz-Lemoine, E; Bergerat, JP; Bordigoni, P; Cahn, JY; Colombat, P; Lutz, P; Pico, JL; Plouvier, E; Reiffers, J; Souillet, G, 1991) |
| "Boys with acute lymphoblastic leukemia (ALL) who have overt testicular relapse (OTR) during initial continuation chemotherapy or within 6 months thereafter have poor outcomes, with long-term survival similar to patients with marrow relapse during treatment." | ( Boyett, JM; Buchanan, GR; Crist, WM; Ghim, T; Johnson, W; Pollock, BH; Smith, SD; Vietti, TJ; Wharam, MD; Yanofsky, RA, 1991) |
| "The treatment of children with acute lymphoblastic leukemia was conducted with the use of 06-Paris-LA-66 program modified by the authors." | ( Kovrigina, TI; Mendeleev, IM; Polezhaev, IuN, 1991) |
| "A human common acute lymphoblastic leukemia (ALL) cell line, REH, was treated in vitro with gamma-interferon (gamma-IFN) or 12-O-tetradecanoylphorbol 13-acetate (TPA)." | ( al-Katib, A; Blaustein, J; Mohammad, RM; Patel, B, 1990) |
| "These data indicate that chemotherapy of acute lymphoblastic leukemia in boys damages testicular function, but more than 2 years later the spermatogenesis as well as endocrine function is expected to recover gradually." | ( Ishii, H, 1990) |
| "Seven adult patients with untreated acute lymphocytic leukemia (ALL) who manifested 5% to 40% myeloperoxidase (MPO)-positive blasts by electron microscopy (EM) are reported." | ( Freireich, EJ; Hirsch-Ginsberg, C; Huh, Y; Kantarjian, HM; Stass, S; Yee, G, 1990) |
| "In treatment of childhood ALL, prevention of CNS relapse by cranial irradiation is followed by considerable long-term sequelae." | ( Bührer, C; Henze, G; Hofmann, J; Reiter, A; Riehm, H; Schellong, G, 1990) |
| "A 14-year-old boy, suffering from acute lymphoblastic leukemia with meningeal involvement, was treated with intraventricular methotrexate and cytosine arabinoside, administered via an Ommaya reservoir (OR)." | ( Balter, R; Borgna-Pignatti, C; Caraballo, R; Colamaria, V; Dalla Bernardina, B; Marradi, P; Mazza, C; Procacci, C, 1990) |
| "Many long term survivors of childhood acute lymphoblastic leukemia have short stature, as well as craniofacial and dental abnormalities, as side effects of central nervous system prophylactic therapy." | ( Howes, A; Mullenix, PJ; Schunior, A; Tarbell, NJ; Tassinari, MS; Zengel, AE, 1990) |
| "We have treated 20 adult patients with acute lymphoblastic leukemia (ALL) and 2 patients with lymphoblastic lymphoma with a protocol modified from L-10M of the Memorial Sloan Kettering Cancer Center." | ( Atogami, S; Kuriyama, K; Maeda, T; Miyazaki, Y; Murata, K; Nagai, K; Nonaka, H; Satoh, T; Tokunaga, S; Yanagisako, T, 1990) |
| "Children with acute lymphocytic leukemia (ALL) in remission were treated with overlapping sequential infusions of methotrexate (MTX) and 1-beta-D-arabinofuranosylcytosine (araC) as part of continuation therapy." | ( Harris, MB; Krance, RA; Newman, EM; Pinkel, D; Ravindranath, Y; Testi, AM; Villacorte, DG, 1990) |
| "A 38-year-old female with acute lymphoblastic leukemia developed monoplegia of the left upper extremity following chemotherapy for remission induction consisting of vincristine, prednisolone, cyclophosphamide, adriamycin and methotrexate." | ( Harada, M; Hayashi, S; Kubota, T; Nagafuchi, S; Niho, Y; Ohtsuka, T; Okamura, T; Shibuya, T, 1990) |
| "Immediately after induction therapy for acute lymphoblastic leukemia, a 2 1/2-year-old child developed invasive pulmonary aspergillosis revealed by pneumothorax, an unusual manifestation." | ( Deschildre, A; Hue, V; Leclerc, F; Martinot, A; Nelken, B, 1990) |
| "Four samples of acute lymphoblastic leukemia (ALL) were treated with low molecular weight B-cell growth factor (15 kDa) and recruitment of aneuploid cells from G0 to G1 was found in all patients (from 19." | ( Andreeff, M; Hegewisch-Becker, S; Tafuri, A, 1990) |
| "In a female with acute lymphoblastic leukemia, inadvertent doxorubicin administration intrathecally caused severe, life-threatening, acute encephalopathy with high-pressure hydrocephalus." | ( Aricó, M; Burgio, GR; Caselli, D; Nespoli, L; Porta, F; Raiteri, E, 1990) |
| "Thirty-nine patients with relapsed acute lymphoblastic leukemia (ALL) and four with primarily refractory ALL were treated with a regimen that included cytarabine 1 gm/m2 (2-hour infusion) twice daily days 1 to 5, mitoxantrone 12mg/m2 daily days 1 to 5, prednisone 0." | ( Auzanneau, G; Gisselbrecht, C; Gratecos, N; Harousseau, JL; LeBlond, V; Michallet, M; Milpied, N; Sebban, C; Troussard, X; Witz, F, 1990) |
| "Eighteen adults with acute lymphoblastic leukemia (ALL) including 14 previously untreated and 4 relapsed cases were treated with individualized and intensified induction and post-remission therapy." | ( Ito, T; Komatsu, M; Saito, Y; Takahashi, H; Toyota, T; Uzuka, Y, 1990) |
| "In a second study, 12 children with acute lymphoblastic leukemia receiving mercaptopurine in the morning had their medication administration switched to the evening." | ( Giesbrecht, E; Greenberg, M; Koren, G; Langevin, AM; Olivieri, N; Zipursky, A, 1990) |
| "13 patients with refractory or relapsed acute lymphoblastic leukemia (ALL) and 7 patients with acute myeloid leukemia (AML) were treated with a regimen that included idarubicin 12 mg/m2 intravenously daily for 3 d plus cytarabine 2 g/m2 by infusion over 3 hours daily for 3 d." | ( Carella, AM; D'Amico, T; Damasio, E; Gaozza, E; Giordano, D; Nati, S; Piatti, G; Pungolino, E; Spriano, M, 1989) |
| "Since April, 1978 to October, 1988, 66 acute lymphocytic leukemia (ALL) patients aged 15 to 79 (21 L1, 43 L2, 2 L3/6 Ph1+) were treated with 3 different therapeutic protocols." | ( Hayashi, N; Inagaki, N; Matuzaki, T; Nakada, H; Nishimura, M; Nonaka, K; Osada, K; Sekito, N; Takahashi, I; Takeuchi, M, 1989) |
| "Twenty children with acute lymphoblastic leukemia (ALL) in relapse were treated with various combinations of anti-leukemic agents in approach to the induction of remission." | ( Ikeda, Y; Ito, E; Ito, R; Miyano, T; Onodera, N; Saito, T; Sato, Y; Suto, Y; Tachibana, N; Tateoka, N, 1989) |
| "We report here a patient with acute lymphoblastic leukemia (ALL) in whom hypofibrinogenemia developed during chemotherapy." | ( Baba, Y; Fujieda, H; Hojo, H; Ohyashiki, JH; Ohyashiki, K; Toyama, K, 1989) |
| "We present two children with acute lymphocytic leukemia who developed leukoencephalopathy following administration of a combination of intravenous ara = C and methotrexate during the consolidation phase of chemotherapy." | ( Bodensteiner, JB; Gay, CT; Nitschke, R; Sexauer, C; Wilson, D, 1989) |
| "Thirteen children with acute lymphoblastic leukemia (ALL) were investigated before and during cytotoxic therapy." | ( Benninger, C; Brandeis, WE; Lichter-Konecki, U; Matthis, P; Scheffner, D, 1987) |
| "Of 53 children with acute lymphoblastic leukemia (ALL) in maintenance treatment with MTX and 6-mercaptopurine (6-MP), 25 had received daily folic acid supplements in vitamin tablets containing 75-200 micrograms folic acid for at least the preceding 3-month period." | ( Clausen, N; Ostergård, E; Pressler, T; Schrøder, H, 1986) |
| "Many children with acute lymphoblastic leukemia (ALL) develop a marrow relapse during or shortly following initial continuation chemotherapy." | ( Boyett, JM; Buchanan, GR; Chauvenet, AR; Crist, WM; Rivera, GK; Vietti, TJ, 1988) |
| "Twelve children with acute lymphoblastic leukemia on maintenance therapy protocols prescribing either 7." | ( Balis, FM; Doherty, KM; Evans, WE; Jeffries, S; McCully, C; Mirro, J; Murphy, RF; Poplack, DG; Reaman, GH, 1988) |
| "20 consecutive adult patients with acute lymphoblastic leukemia were treated with an intense induction regimen including vincristine, doxorubicin, prednisolone, L-asparaginase and cyclophosphamide." | ( Killander, A; Simonsson, B; Smedmyr, B; Sundström, C, 1988) |
| "Leydig cell function in 21 boys with acute lymphoblastic leukemia who had been treated by bilateral direct testicular irradiation (12 X 2 Gy) at 8." | ( Brauner, R; Caltabiano, P; Leverger, G; Rappaport, R; Schaison, G, 1988) |
| "Early and late effects of treatment for acute lymphoblastic leukemia (ALL) on weight was retrospectively investigated in 113 children in continuous first remission." | ( De Groot, A; Egeler, RM; Hählen, K; Hokken-Koelega, AC; Tromp, CG; Van Dongen-Melman, JE, 1995) |
| "In 20 Dutch children with acute lymphoblastic leukemia (ALL), Cu and Zn levels in cerebrospinal fluid (CSF) were studied during standard treatment (Protocol ALL-BFM-86/SNWLK-ALL-VII)." | ( Van Weel-Sipman, MH; Van Wouwe, JP, 1993) |
| "In children treated for acute lymphoblastic leukemia (ALL), catch-up growth occurs after cessation of therapy and not during maintenance therapy." | ( Groot-Loonen, JJ; Lippens, RJ; Otten, BJ; Stoelinga, GB; van t' Hof, MA, 1995) |
| "Thus we conclude that in childhood acute lymphoblastic leukemia, hyperleukocytosis can be managed safely and effectively with intravenous hydration, urinary alkalinization, and allopurinol before starting any specific anti-leukemic chemotherapy avoiding risk-associated cranial irradiation, leukapheresis, and exchange transfusion." | ( Advani, SH; Basade, M; Dhar, AK; Kulkarni, SS; Kurkure, PA; Nair, CN; Pai, SK; Parikh, BS; Sastry, PS; Yadav, RP, 1995) |
| "In 91 of 106 adult patients with acute lymphoblastic leukemia (ALL) enrolled in the treatment protocol ALL HOVON-5 between May 1988 and October 1991, the immunophenotype of the leukemia was determined and correlated with clinical characteristics at presentation." | ( Dekker, AW; Kluin-Nelemans, JC; Löwenberg, B; Ossenkoppele, GJ; Schouten, HC; Sizoo, W; van Putten, WL; van't Veer, MB; Verdonck, LF; Wijermans, PW, 1993) |
| "Since October 1984, children with acute lymphoblastic leukemia (ALL) were treated with six protocols of the Kyushu-Yamaguchi Children's Cancer Study Group (KYCCSG)." | ( Inoue, T; Ishihara, T; Ishii, E; Koga, H; Matsuzaki, A; Miyazaki, S; Nibu, K; Take, H; Ueda, K; Yanai, F, 1995) |
| "Two groups of children with acute lymphoblastic leukemia or non-Hodgkin lymphoma, treated with anthracyclines (ANT), were studied: group I, consisting of 10 patients, with coenzyme Q10 (CoQ) therapy; group II, consisting of 10 patients without CoQ therapy." | ( Agretto, A; Auricchio, U; Casale, F; Giuliano, M; Iacono, A; Iarussi, D; Indolfi, P; Murano, A, 1994) |
| "Therapy for group non-B patients (lymphoblastic lymphoma and pleomorphic T-cell lymphoma [PTCL]) consisted of a Berlin-Frankfurt-Münster (BFM) acute lymphoblastic leukemia protocol, including cranial irradiation for advanced stage." | ( Gadner, H; Henze, G; Ludwig, WD; Müller-Weihrich, S; Parwaresch, R; Reiter, A; Riehm, H; Sauter, S; Schrappe, M; Sykora, KW, 1995) |
| "The clinical outlook for adults with acute lymphoblastic leukemia (ALL) has improved with the use of intensive chemotherapy." | ( Welborn, JL, 1994) |
| "Sixty-one consecutive patients with acute lymphoblastic leukemia (ALL) (B-ALL excluded) were treated with the protocol described by Hoelzer et al." | ( Bettelheim, P; Geissler, K; Jäger, U; Knöbl, P; Kyrle, PA; Laczika, K; Mitterbauer, G; Neumann, E; Scherrer, R; Schneider, B, 1994) |
| "A total of 42 adults with acute lymphoblastic leukemia were treated with an aggressive induction/consolidation chemotherapy (MCP-841) between June 1986 and December 1991." | ( Advani, IM; Gopal, R; Nadkarni, K; Pai, S; Pai, V; Parikh, P; Raje, N; Saikia, T; Vaidya, S, 1994) |
| "Thirty-five children with acute lymphoblastic leukemia were monitored weekly during the first 12 weeks of chemotherapy." | ( Kivivuori, SM; Siimes, MA; Teppo, AM; Viinikka, L, 1994) |
| "We studied 106 untreated childhood acute lymphoblastic leukemia (ALL) samples with > or = 80% leukaemic cells at the start of culture." | ( Broekema, GJ; Hählen, K; Huismans, DR; Kaspers, GJ; Kazemier, KM; Loonen, AH; Pieters, R; Rottier, MA; van Zantwijk, CH; Veerman, AJ, 1994) |
| "Fifty consecutive adult patients with acute lymphoblastic leukemia (ALL) were treated with an intensive cyclical chemotherapy and the mean received dose of individual cytotoxic drug was retrospectively studied." | ( Chan, LC; Chan, TK; Chiu, EK; Kwong, YL; Liang, R; Lie, A; Todd, D, 1994) |
| "In the past 16 years, 2004 children with acute lymphoblastic leukemia (ALL) have been treated in the Polish Pediatric Group centers." | ( Armata, J; Balwierz, W; Bogusławska-Jaworska, J; Chybicka, A; Jackowska, T; Jakowicka, M; Kulus, M; Matysiak, M; Michalewska, D; Ochocka, M, 1993) |
| "The majority of children with acute lymphoblastic leukemia (ALL; 12 of 14 [86%]) undergoing maintenance chemotherapy were able to resume full-dose therapy." | ( Briones, G; Cairo, MS; Frost, JD; Weinthal, J, 1994) |
| "When patients with common acute lymphoblastic leukemia (cALL) and acute myeloblastic leukemia (AML) were treated with prednisolone (60 mg/m2/day, p." | ( Adachi, S; Akiyama, Y; Hirota, H; Kubota, M; Kuwakado, K; Matsubara, K; Mikawa, H; Wakazono, Y, 1994) |
| "From 1975 to 1989, 71 acute lymphoblastic leukemia patients aged 15 to 81 years (median 46 years) were treated at Jichi Medical School." | ( Akutsu, M; Furukawa, Y; Imagawa, S; Iwama, A; Komatsu, N; Kurata, H; Suzuki, T; Tsunoda, J; Tsunoda, S; Yoshida, M, 1993) |
| "Twenty patients with relapsed acute lymphocytic leukemia were given teniposide as part of their induction and maintenance therapy." | ( Evans, WE; Furman, WL; Rivera, G; Rodman, JH; Sunderland, M, 1993) |
| "Thirty-one children with acute lymphoblastic leukemia (ALL) who had received cranial radiation therapy (CrRT) and five concomitant doses of intrathecal methotrexate (IT MTX) for central nervous system prophylaxis (CNSP) and who had an event-free survival exceeding 5 years had cranial computed tomography (Cr CT) examination." | ( Hsieh, YL; Huang, JK; Liang, DC; Lin, JC; Lin, ST; Shih, SL; Shu, SG; Tsai, YM; Wong, LY; Yang, CP, 1993) |
| "In four of 14 patients with acute lymphoblastic leukemia (ALL) who received induction chemotherapy containing weekly injections of vincristine and simultaneous antifungal prophylaxis with itraconazole, unusually severe and early vincristine-induced neurotoxicity was observed." | ( Böhme, A; Ganser, A; Hoelzer, D, 1995) |
| "Herein we describe a 6-year-old boy with acute lymphoblastic leukemia who received an inadvertent overdose of 600 mg of IT administered MTX instead of the intended dose of 12 mg." | ( Adamson, PC; Johnson, CM; McManus, MJ; O'Marcaigh, AS; Patterson, MC; Smithson, WA; Widemann, BC, 1996) |
| "In acute lymphoblastic leukemia (ALL), the role of agreement regarding ANT dosage and schedule, preferable compound, and indications for remission induction and consolidation treatment phases." | ( Barbui, T; Bassan, R; Lerede, T; Rambaldi, A, 1996) |
| "A 45-year-old woman with acute lymphoblastic leukemia (ALL) who failed to achieve complete remission (CR) after one course of induction chemotherapy with vincristine, daunorubicin, prednisolone and l-asparaginase was successfully treated with a high dose of cytosine arabinoside (Ara-C) and mitoxantrone." | ( Ikeda, Y; Ishida, A; Kawai, Y; Kizaki, M; Nakajima, H; Tokuhira, M; Watanabe, K, 1996) |
| "Two boys with acute lymphocytic leukemia (ALL) who presented with muscle pain, shortly after receiving induction chemotherapy, were evaluated." | ( Corden, TE; Morgan, ER, 1996) |
| "A 35-year-old man with B lymphoblastic lymphoma was treated with bone marrow transplant and aggressive chemotherapy." | ( Arrese, JE; Piérard, GE; Piérard-Franchimont, C, 1996) |
| "Four of 55 (7%) adult acute lymphocytic leukemia patients, age 27-58 years, who were treated with methotrexate, vincristine, L-asparaginase, and dexamethasone (MOAD) developed avascular necrosis (AVN) of one or both femoral heads 16-39 months after beginning treatment." | ( Hui, L; Wiernik, PH, 1996) |
| "Children with acute lymphoblastic leukemia (ALL) have impairment in their neuropsychological functioning and morphological changes in their brain after cranial irradiation and chemotherapy." | ( Ahonen, AK; Harila-Saari, AH; Himanen, AS; Lanning, BM; Pääkkö, EL; Pyhtinen, J; Torniainen, PJ; Vainionpää, LK, 1997) |
| "Acute lymphoblastic leukemia (L3) was initially diagnosed because of poor staining of alpha-naphtyl butylate esterase and induction chemotherapy with the LVP regimen (L-asparaginase 5,000 U/m2 day 8-21, vincristine 1." | ( Fujita, H; Kobayashi, S; Kodama, F; Koharazawa, H; Maruta, A; Okubo, T; Tomita, N; Yamamoto, T, 1997) |
| "Secondary therapy-related, acute lymphoblastic leukemia (S-ALL) is less common than its myeloblastic counterpart." | ( Bayle, C; Carde, P; Macintyre, E; Nasr, F; Ribrag, V; Venuat, AM, 1997) |
| "A total of 119 children (1990-95) with acute lymphoblastic leukemia (ALL) B-lineage either CD10+ or CD10- were registered into a single non-randomized chemotherapy protocol." | ( Cardenas-Cardos, R; Gómez-Martínez, R; Leal-Leal, C; Meza-Coria, C; Navarro-Alegría, I; Rivera-Luna, R; Vega-Vega, L, 1997) |
| "Treatment failure in newly diagnosed childhood ALL can be predicted based on cellular drug resistance data." | ( Kaspers, GJ; Pieters, R; Smets, LA; Van Der Does-Van Den Berg, A; Van Wering, ER; Van Zantwijk, CH; Veerman, AJ, 1997) |
| "Twenty-four pediatric patients with acute lymphoblastic leukemia (ALL) on maintenance therapy were evaluated for their compliance with taking their prescribed doses of oral mercaptopurine (6-MP)." | ( Greenberg, M; Koren, G; Lau, RC; Matsui, D, 1998) |
| "Therapy of children with relapsed acute lymphoblastic leukemia (ALL) not achieving a second remission (CR2) after an initial reinduction attempt is problematic." | ( Feig, SA; Harris, RE; Sather, HN, 1998) |
| "We report a 20-month-old boy with acute lymphoblastic leukemia with the 11q23 translocation whose blasts markedly increased in peripheral blood after intravenous granulocyte colony-stimulating factor (G-CSF) administration, but disappeared after stopping G-CSF." | ( Goi, K; Iijima, K; Inukai, T; Kagami, K; Kinoshita, A; Kojika, S; Mori, T; Nakazawa, S; O-Koyama, T; Sugita, K; Suzuki, T; Tezuka, T, 1998) |
| "Acute lymphoblastic leukemia (ALL) in infants has a very poor outcome with modern chemotherapy." | ( Haut, P; Kletzel, M; Marymount, M; Morgan, E; Pirich, L, 1999) |
| "Patients with acute lymphocytic leukemia (ALL) and those with lymphoblastic lymphoma (LBL) have overlapping clinical and immunophenotypic features and they have been treated with the same or very similar chemotherapy regimens." | ( Abe, T; Aoki, I; Araki, K; Deura, K; Fukuda, H; Fukuhara, S; Hotta, T; Kobayashi, T; Konda, S; Kozuru, M; Matsumoto, M; Mikuni, C; Nagai, M; Niimi, M; Oyama, A; Sai, T; Shimoyama, M; Shirakawa, S; Tajima, K; Tobinai, K; Toki, H; Yamaguchi, N, 1999) |
| "Treatment of childhood acute lymphoblastic leukemia has included glucocorticosteroids for almost 50 years." | ( Carrel, AL; Gaynon, PS, 1999) |
| "Patients with refractory or recurrent acute lymphoblastic leukemia (ALL) were treated with a combination of methotrexate (MTX), vincristine, PEG-asparaginase, and prednisone (MOAP)." | ( Aguayo, A; Cortes, J; Kantarjian, H; Keating, M; Pierce, S; Thomas, D, 1999) |
| "Patients with acute lymphoblastic leukemia are often treated with 6-mercaptopurine, and those with homozygous deficiency in thiopurine S-methyltransferase (TPMT) enzyme activity have an extreme sensitivity to this drug as a result of the accumulation of higher cellular concentrations of thioguanine nucleotides." | ( Evans, WE; Hancock, ML; Krynetski, EY; Pui, CH; Relling, MV; Ribeiro, RC; Rivera, GK; Sandlund, JT, 1999) |
| "In a prior study, primary resistant acute lymphoblastic leukemia (RES-ALL) was observed in 11 of 176 (6%) adult patients treated with a four drug regimen (IVAP), its incidence being higher in T-cell or Philadelphia (Ph) chromosome/BCR-ABL rearrangement positive ALL cases with a blast cell count >25x10(9)/L (RES-ALL rate 19%, p=0." | ( Barbui, T; Bassan, R; Casula, P; Corneo, G; Coser, P; Fabris, P; Izzi, T; Lambertenghi-Deliliers, G; Lerede, T; Morandi, S; Pogliani, E; Rossi, G; Vespignani, M, 1999) |
| "Children with acute lymphoblastic leukemia (ALL) who experience hematologic recurrence while receiving chemotherapy or within 6 months after its cessation have a low cure rate." | ( Boyett, JM; Buchanan, GR; Chauvenet, AR; Crist, WM; Maybee, DA; Pinkel, D; Pollock, BH; Rivera, GK; Wagner, H, 2000) |
| "Treatment for childhood ALL with cranial irradiation and chemotherapy at a young age is clearly associated with poorer academic career." | ( Kingma, A; Postma, A; Rammeloo, LA; Rekers-Mombarg, L; van Der Does-van den Berg, A, 2000) |
| "To assess the effects of treatment for acute lymphoblastic leukemia (ALL) on children's cognitive functioning." | ( Holdaway, D; Lawrence, B; Raymond-Speden, E; Tripp, G, 2000) |
| "Ten children with early B-cell lineage acute lymphoblastic leukemia were evaluated by cosyntropin (corticotropin (1-24)) stimulation testing before initiation of dexamethasone therapy and every 4 weeks thereafter until adrenal function returned to normal." | ( Dickson, BA; Felner, EI; Ratliff, AF; Thompson, MT; White, PC, 2000) |
| "Nineteen pediatric patients affected by acute lymphoblastic leukemia (ALL) were examined weekly with respect to 6-mercaptopurine nucleotide (6-MPN) and 6-thioguanine nucleotide (6-TGN) levels in erythrocytes during the course of maintenance treatment with 6-MP 50 mg/m2 per d and results were related to various parameters of bone marrow function to assess, in the same individual, the level of reliability of 6-MP metabolites in predicting a later change in peripheral blood cell counts." | ( Barachini, S; Barbara, C; Bocci, G; Casazza, G; Danesi, R; Del Tacca, M; Di Paolo, A; Favre, C; Fogli, S; Innocenti, F; Macchia, P; Menconi, MC; Nardi, M, 2000) |
| "The prognosis of patients with acute lymphoblastic leukemia (ALL) in childhood has improved with intensive chemotherapy." | ( Kishi, T; Tanaka, Y; Ueda, K, 2000) |
| "A 15-year-old boy with T-cell acute lymphoblastic leukemia (ALL) (FAB L1), diagnosed in 1995, received combination chemotherapy consisting of 6 weeks of induction (vincristine, epirubicin, L-asparaginase, prednisolone) and 2 weeks of consolidation (cytosine arabinosides, etoposide)." | ( Chan, HL; Jaing, TH; Yang, CH; Yang, LJ, 2000) |
| "Secondary tumor disease (acute lymphoblastic leukemia) was diagnosed in one cases 14 years after diagnosis of Hodgkin's disease stage IIb, which was treated with radiation and standard chemotherapy, and 10 years after combination chemotherapy using NMU as a component for relapse." | ( Korman, DB, 2000) |
| "We report on a 62-year-old woman with acute lymphoblastic leukemia (first diagnosis November 1997) receiving chemotherapy with 2,340 mg methotrexate over 24 hours." | ( Dempke, W; Schmoll, HJ; von Poblozki, A, 2000) |
| "Children treated for acute lymphoblastic leukemia may develop reduced bone mineral density during treatment, but there is little information on the mechanisms involved." | ( Ahmed, SF; Crofton, PM; Elmlinger, MW; Kelnar, CJ; Ranke, MB; Wade, JC; Wallace, WH, 2000) |
| "Treatment of childhood acute lymphoblastic leukemia (ALL) may cause structural and functional brain damage." | ( Harila-Saari, A; Himanen, S; Lanning, M; Pääkkö, E; Pyhtinen, J; Vanionpää, L, 2000) |
| "Nineteen of 35 children (54%) with acute lymphoblastic leukemia receiving maintenance therapy consisting of daily oral 6-mercaptopurine and weekly oral methotrexate developed hypoglycemia (blood glucose level <2." | ( Halonen, P; Mäkipernaa, A; Salo, MK, 2001) |
| "Our results showed that in children with acute lymphoblastic leukemia, anticancer chemotherapy decreased liver metabolic capacity." | ( Boguslawska-Jaworska, J; Golebiowski, W; Gorczynska, E; Hurkacz, M; Orzechowska-Juzwenko, K; Wiela-Hojenska, A, 2001) |
| "Most prognostic factors in childhood acute lymphoblastic leukemia (ALL) are informative for groups of patients, whereas new approaches are needed to predict the efficacy of chemotherapy for the individual patient." | ( Kaspers, GJ; Knabe, N; Madsen, HO; Nyvold, C; Pieters, R; Rottier, MM; Ryder, LP; Schmiegelow, K; Seyfarth, J; Svejgaard, A, 2001) |
| "Glucocorticoid treatment in childhood acute lymphoblastic leukemia increases energy intake markedly, and this effect contributes to the excess weight gain and obesity characteristic of patients being treated for acute lymphoblastic leukemia." | ( Brougham, M; Gibson, BE; Kelly, A; Montgomery, C; Reilly, JJ; Richardson, F, 2001) |
| "Forty-one consecutive children with acute lymphoblastic leukemia (ALL) received prophylaxis therapy with the low molecular weight heparin (LMWH) enoxaparin during L-asparaginase treatment." | ( Ben Barak, A; Brenner, B; Elhasid, R; Lanir, N; Levin, C; Postovsky, S; Sharon, R; Weyl Ben Arush, M, 2001) |
| "We studied 170 patients with acute lymphoblastic leukemia (ALL), treated from 1988 to 1994 according to a protocol derived from BFM-83 studies, in order to evaluate the incidence and prognostic significance of mutations in this gene in childhood ALL." | ( Clementino, NC; Costa, FF; Figueiredo, MS; Kerbauy, J; Saad, ST; Viana, MB; Yamamoto, M, 2001) |
| "To report four acute lymphoblastic leukemia(ALL) patients who developed tumor lysis syndrome(TLS) after initial chemotherapy." | ( Han, M; He, H; Li, C, 1999) |
| "Children with acute lymphoblastic leukemia are treated with intensive chemotherapy resulting in profound immuno suppression." | ( Agger, KE; Carlsen, NT; Rosthøj, S; Schmiegelow, K; Schrøder, H, 2001) |
| "All were undergoing chemotherapy for acute lymphocytic leukemia (ALL) or acute myelocytic leukemia (AML)." | ( Danahey, D; Malhotra, PS; Sidman, J, 2001) |
| "A 56-year-old woman with Ph1--Positive acute Lymphoblastic Leukemia was admitted to our hospital for induction chemotherapy in June 1999." | ( Kinoshita, S; Nishio, H; Sakakibara-Kawamura, K; Suzuki, T; Utsumi, T, 2002) |
| "Even though acute lymphoblastic leukemia (ALL) responds well to chemotherapy, relapse remains the major problem." | ( Botsonis, A; Moschovi, M; Papadopoulou, AL; Tsangaris, GT; Tzortzatou-Stathopoulou, F, 2001) |
| "A 5-year-old girl with acute lymphoblastic leukemia developed a severe but transient radiculopathy after intrathecal administration of methotrexate and cytarabine for an isolated central nervous system relapse." | ( Antunes, NL; Lis, E; Rosenblum, M; Souweidane, MM; Steinherz, PG; Wolden, S, 2002) |
| "Extending the principle of conventional acute lymphoblastic leukemia (ALL) therapy to transplantation, 77 adult patients receiving autografts in first remission after melphalan with or without total body irradiation were scheduled to receive 6-mercaptopurine (6MP), methotrexate (MTX), and vincristine-prednisone (VP) for 2 years after transplantation to reduce relapse." | ( Kulkarni, S; Mehta, J; Powles, R; Singhal, S; Sirohi, B; Tait, D; Treleaven, J, 2002) |
| "In acute lymphoblastic leukemia (ALL), treatment with granulocyte colony stimulating factor (G-CSF) during remission induction shortens granulocytopenia and may decrease morbidity due to infections." | ( Balleisen, L; Bergmann, L; Fiedler, F; Franke, A; Ganser, A; Gökbuget, N; Hartmann, F; Hoelzer, D; Hofmann, WK; Huber, C; Illiger, HJ; Langenhan, S; Ottmann, OG; Pasold, R; Pott, C; Rasche, H; Reutzel, R; Rudolph, C; Schoeffski, O; Schott, D; Seipelt, G, 2002) |
| "It is concluded that good results in childhood ALL treatment can be achieved without resorting to high-dosage chemotherapy and radiation in most cases." | ( Dudkin, SD; Dyshlevaia, ZM; Fechina, LG; Hartmann, R; Henze, H; Karachunskiĭ, AI; Lebedev, VV; Miakova, NV; Rudneva, AE; Rumiantsev, AG; Shamardina, AV; Timakov, AM; Timofeeva, VN; Trubina, NM; Varfolomeeva, SR, 2002) |
| "During treatment of acute lymphoblastic leukemia, serious gastrointestinal complications rarely occur in children." | ( Barabino, A; Castagnola, E; Dini, G; Dufour, C; Fioredda, F; Haupt, R; Micalizzi, C, 2002) |
| "Treatment results in childhood ALL continue to improve, and the expected current cure rates approach 75 to 80% of all children with ALL, including T-ALL and mature B-cell ALL, the two variants that, not too long ago, had a considerably poorer prognosis compared with the common form of BpALL." | ( Ravindranath, Y, 2003) |
| "Conventional therapy for childhood acute lymphoblastic leukemia (ALL) includes prednisone and oral 6-mercaptopurine." | ( Bostrom, BC; Erdmann, GR; Gaynon, PS; Gold, S; Heerema, NA; Hutchinson, RJ; Johnston, K; La, MK; Provisor, AJ; Sather, HN; Sensel, MR; Trigg, ME, 2003) |
| "A five years old child with acute lymphoblastic leukemia presented after 30 months of treatment a bilateral hypopyon." | ( Benkirane, N; Berraho, A; Charif, CM; Loughzail, K, 2002) |
| "Adults with untreated acute lymphoblastic leukemia (ALL) were treated with a previously developed and tested chemotherapeutic regimen." | ( Bloomfield, CD; Dodge, RK; Frankel, SR; Hurd, DD; Kolitz, JE; Larson, RA; Reynolds, C; Schiffer, CA; Sklar, J; Stewart, CC; Stone, RM; Szatrowski, TP; Velez-Garcia, E; Westbrook, CA, 2003) |
| "Erythrocyte TGNs concentration in acute lymphoblastic leukemia (ALL) patients after 6-MP treatment was detected by high-performance liquid chromatography (HPLC)." | ( Chen, J; Gu, LJ; Liang, AB; Tang, YN; Xue, HL; Ye, QD; Ye, YC; Zhao, JC, 2003) |
| "Therapy for childhood acute lymphoblastic leukemia (ALL) is entering a new era in terms of quality-of-life." | ( Moriwake, T; Nishiuchi, R; Oda, M; Seino, Y; Tanaka, H; Yamashita, N, 2003) |
| "Four children on chemotherapy for acute lymphoblastic leukemia presented with severe diarrhea and dehydration." | ( Jumaa, P; Nawaz, A; Trad, O; Uduman, S, 2003) |
| "Ina 24-month-old girl with acute lymphoblastic leukemia and invasive aspergillosis, only combination therapy with liposomal amphotericin B and caspofungin achieved a good response." | ( Dupuis, W; Elanjikal, Z; Jautzke, G; Klingebiel, T; Lehrnbecher, T; Schmidt, H; Sörensen, J; Tintelnot, K, 2003) |
| "Three children with acute lymphoblastic leukemia presenting with hyperuricemia received rasburicase as a single intravenous dose just prior to the start of chemotherapy." | ( Chan, R; Lee, AC; Li, CH; So, KT, 2003) |
| "A 57-year-old woman with acute lymphoblastic leukemia (ALL) developed an antibiotics-resistant fever after remission induction therapy." | ( Funahashi, K; Kato, Y; Kohno, A; Morishita, Y; Narimatsu, H; Ozeki, K; Saito, S; Shimada, K, 2003) |
| "Although the majority of children with acute lymphoblastic leukemia (ALL) are cured with combination chemotherapy containing methotrexate (MTX), drug resistance contributes to treatment failure for a substantial fraction of patients." | ( Arush, MW; Assaraf, YG; Cole, PD; Drori, S; Elhasid, R; Ifergan, I; Jansen, G; Kamen, BA; Kaspers, GJ; Kaufman, Y; Matherly, LH; Rechavi, G; Sahar, D; Sirota, J; Toren, A, 2004) |
| "In all, 625 patients with acute lymphoblastic leukemia (ALL) entered the Leucémie Aiguë Lymphoblastique de l'Adulte-94 trial from June 1994 to June 1999, and received a 4-week induction therapy followed either by chemotherapy alone or stem cell transplantation (SCT)." | ( Boiron, JM; Buzyn, A; Delannoy, A; Fegueux, N; Fière, D; Gardin, C; Georges, M; Hacini, M; Huguet, F; Kuentz, M; Lhéritier, V; Micléa, JM; Reman, O; Stamatoullas, A; Thomas, X; Vernant, JP, 2004) |
| "Treatment for acute lymphoblastic leukemia (ALL) in childhood results in a reduction in bone mineral density (BMD)." | ( Atkinson, S; Barr, RD; Mandel, K; Pencharz, P, 2004) |
| "Although childhood acute lymphoblastic leukemia (ALL) is highly responsive to chemotherapy, reliable techniques are needed to determine treatment outcome and predict impending relapse." | ( Bandyopadhyay, S; Bhattacharya, DK; Chatterjee, M; Hall, AG; Mandal, C; Minto, L; Pal, S, 2004) |
| "Up to 80% of pediatric patients with acute lymphoblastic leukemia (ALL) can be cured if intensive therapy is applied." | ( Schrappe, M, 2004) |
| "Children with acute lymphoblastic leukemia rarely are overtly malnourished, which makes this population ideal for an investigation of the relations between dietary antioxidant consumption, plasma antioxidant concentrations, and chemotherapy-induced toxicity." | ( Blumberg, J; Kelly, KM; Kennedy, DD; Ladas, ED; Rheingold, SR; Tucker, KL, 2004) |
| "A 40-year-old Hispanic man with acute lymphoblastic leukemia was treated with a single dose of intrathecal methotrexate 12 mg for prophylaxis against leptomeningeal spread of tumor." | ( Brock, S; Jennings, HR, 2004) |
| "Thirty children with high-risk non-B acute lymphoblastic leukemia (ALL) treated according to the national protocol (PINDA 92) based on ALL BFM 90, were randomized to receive consolidation with four doses of either 1 or 2 g/m(2) MTX as a 24-hr infusion, at 2-week intervals (group M1 and M2, respectively)." | ( Campbell, M; Joannon, P; Oviedo, I; Tordecilla, J, 2004) |
| "Therapy of lymphoblastic lymphoma (LL) has evolved with use of chemotherapy regimens modeled after those for acute lymphocytic leukemia (ALL)." | ( Beran, M; Cabanillas, F; Cortes, J; Faderl, S; Ferrajoli, A; Giles, FJ; Ha, CS; Kantarjian, H; Keating, MJ; Koller, C; O'Brien, S; Pierce, S; Thomas, DA; Verstovsek, S, 2004) |
| "We treated a 52-year-old woman with acute lymphoblastic leukemia (ALL) who developed invasive pulmonary aspergillosis (IPA) as a result of neutropenia following remission-induction chemotherapy." | ( Asaka, M; Imamura, M; Kahata, K; Kondo, K; Mori, A; Musashi, M; Ota, S; Tanaka, J; Toubai, T; Toyoshima, N, 2004) |
| "Childhood acute lymphoblastic leukemia (ALL) is curable with chemotherapy in approximately 80 percent of patients." | ( Cheng, C; Cheok, MH; den Boer, ML; Evans, WE; Holleman, A; Janka-Schaub, GE; Kazemier, KM; Pei, D; Pieters, R; Pui, CH; Relling, MV; Veerman, AJ; Yang, W, 2004) |
| "The acute lymphoblastic leukemia (ALL) patients were treated for relapsed (7) or refractory disease (10)." | ( Balleari, E; Ballerini, F; Balocco, M; Canepa, L; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Venturino, C, 2004) |
| "In all, 236 adults with newly diagnosed acute lymphoblastic leukemia (ALL) were randomly assigned to receive either granulocyte colony-stimulating factor (G-CSF), or granulocyte-macrophage CSF (GM-CSF), or no CSF during a 4-week 4-drugs induction chemotherapy." | ( Boiron, JM; Boulat, O; Espinouse, D; Fiere, D; Garban, F; Gardin, C; Huguet, F; Lhéritier, V; Reman, O; Sutton, L; Thomas, X; Turlure, P, 2004) |
| "Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, and until recently prophylactic cranial radiotherapy (CRT) was important for achieving long-term survival." | ( Ahrén, B; Björk, J; Cavallin-Ståhl, E; Erfurth, EM; Garwicz, S; Link, K; Moëll, C; Thilén, U, 2004) |
| "Acute lymphoblastic leukemia (ALL) represents a rare malignancy in the elderly and few authors have specifically focused on the treatment of ALL in this setting." | ( Catarini, M; Centurioni, R; Corvatta, L; Leoni, F; Leoni, P; Malerba, L; Marconi, M; Masia, MC; Offidani, M; Scortechini, AR, 2005) |
| "Children undergoing treatment for acute lymphoblastic leukemia (ALL) receive combination chemotherapy and many of the components are associated with free radical production." | ( Blumberg, J; Kelly, KM; Kennedy, DD; Ladas, EJ; Rheingold, SR, 2005) |
| "Patients with T-cell acute lymphoblastic leukemias (T-ALLs) within the Leucemies Aigues Lymphoblastiques de l'Adulte-94 (LALA-94) prospective trial were treated with a 4-drug per 4-week induction, with intermediate-dose cytarabine and mitoxantrone salvage treatment for patients not achieving complete remission (CR) in 1 course." | ( Asnafi, V; Boiron, JM; Buzyn, A; Cayuela, JM; Dombret, H; Fiere, D; Huguet, F; Lheritier, V; Macintyre, E; Reman, O; Thomas, X; Vernant, JP; Vey, N, 2005) |
| "Acute lymphoblastic leukemia (ALL) with Bcr-Abl translocation is one of the most difficult to treat and deadly diseases in children." | ( Hawkins, LM; Jayanthan, AA; Narendran, A, 2005) |
| "The treatment outcome of children with acute lymphoblastic leukemia improved remarkably over the last decades." | ( Bartyik, K; Békési, A; Galántai, I; Jakab, Z; Kajtár, P; Kiss, C; Kovács, G; Magyarosy, E; Masát, P; Müller, J; Nagy, K; Rényi, I, 2005) |
| "Children with acute lymphoblastic leukemia (ALL) receive as part of induction therapy a 4-week course of high-dose glucocorticoid, which is either abruptly discontinued or shortly tapered." | ( Altare, F; Barisone, E; Bertorello, N; Corrias, A; Einaudi, S; Farinasso, L; Pastore, G; Saracco, P, 2005) |
| "Acute lymphoblastic leukemia (ALL) can be cured with combination chemotherapy in over 75% of children, but the cause of treatment failure in the remaining patients is unknown." | ( Cheng, C; Cheok, MH; den Boer, ML; Evans, WE; Holleman, A; Janka-Schaub, GE; Lugthart, S; Pieters, R; Pui, CH; Relling, MV; Yang, W, 2005) |
| "An effective treatment for acute lymphoblastic leukemia (ALL), intravenous (IV) methotrexate (MTX) has a notable toxic effect on the CNS, with leukoencephalopathy (LE) being the most common form." | ( Glass, JO; Helton, KJ; Langston, JW; Pui, CH; Reddick, WE; Wu, S; Xiong, X, 2005) |
| "Acute lymphoblastic leukemia (ALL) in infants is characterized by rearrangements of the mixed lineage leukemia (MLL) gene, drug resistance, and a poor treatment outcome." | ( Armstrong, SA; Beverloo, HB; de Lorenzo, P; den Boer, ML; Horstmann, M; Nollau, P; Pieters, R; Sallan, SE; Schneider, P; Stam, RW; Valsecchi, MG; van der Voort, E, 2005) |
| "A 3-year-old boy diagnosed with acute lymphoblastic leukemia received induction chemotherapy." | ( Bermúdez, M; Fuster, JL; Galera, A; Gonzalez, C; Llinares, E, 2005) |
| "Forty-three young adults, treated for childhood ALL with 18-30 Gy CRT and chemotherapy, were studied, and comparison was made with matched controls." | ( Björk, J; Erfurth, EM; Link, K, 2005) |
| "Seven Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) patients in first complete remission received maintenance therapy with imatinib alone." | ( Luppi, M; Marasca, R; Martinelli, S; Potenza, L; Riva, G; Torelli, G, 2005) |
| "Children with acute lymphoblastic leukemia (ALL) are treated with intermittent steroid therapy." | ( Chauvenet, AR; Hill, G; Lovato, J; McLean, TW, 2005) |
| "A 13-year old boy with acute lymphoblastic leukemia had bilateral paresis of the upper extremities and aphasia 1 week after high dose methotrexate and triple intrathecal therapy (methotrexate, cytarabin, hydrocortisone)." | ( Amano, Y; Asano, T; Fukunaga, Y; Hayakawa, J; Maeda, M; Migita, M; Ueda, T, 2005) |
| "A 21-year-old white male with relapsed acute lymphoblastic leukemia (ALL) developed an invasive Zygomycosis infection 3 weeks after beginning re-induction chemotherapy." | ( Barfield, RC; Behm, FG; Burnette, K; Eldridge, P; Hale, GA; Handgretinger, R; Knapp, K, 2007) |
| "A 13-year-old boy with acute lymphoblastic leukemia was treated for cytomegalovirus retinitis with valganciclovir 450 mg every 2 days in the course of hematopoietic stem cell transplantation." | ( Benketira, A; Blayac, JP; Cociglio, M; Hansel, S; Hillaire-Buys, D; Jalabert, A; Jeziorsky, E; Margueritte, G; Peyrière, H, 2006) |
| "We report the two survivors of childhood ALL treated with chemotherapy without CR who required GH replacement due to absence of catch-up growth." | ( Haddy, TB; Mosher, RB; Nunez, SB; Reaman, GH, 2006) |
| "The authors studied 15 children with acute lymphoblastic leukemia or lymphoblastic lymphoma who were treated using protocols that included high-dose methotrexate (3." | ( Kosaki, K; Mori, T; Samejima, H; Sato, R; Shimada, H; Shimasaki, N; Takahashi, T; Tanigawara, Y; Torii, C; Yahagi, N; Yoshihara, H, 2006) |
| "Survivors of childhood-onset (CO) acute lymphoblastic leukemia (ALL) treated with prophylactic cranial radiotherapy often exhibit GH deficiency (GHD), which is associated with increased prevalence of cardiovascular risk factors and cardiac dysfunction." | ( Ahrén, B; Erfurth, EM; Follin, C; Thilén, U, 2006) |
| "Fifty-two infants with acute lymphoblastic leukemia (ALL) enrolled in the AIEOP ALL-91 and ALL-95 studies were treated with the intermediate or high risk protocols according to their presenting features and early response to treatment." | ( Aricò, M; Basso, G; Biondi, A; De Lorenzo, P; De Rossi, G; Lo Nigro, L; Locatelli, F; Masera, G; Rizzari, C; Valsecchi, MG, 2006) |
| "Thirty-five children with acute lymphoid leukemia (ALL) receiving glucocorticoid therapy (median age of 6." | ( Colosimo, EA; Cunha, CF; Finch, FL; Silva, IN, 2006) |
| "Modern clinical treatments of childhood acute lymphoblastic leukemia (ALL) employ enzyme-based methods for depletion of blood asparagine in combination with standard chemotherapeutic agents." | ( Kilberg, MS; Richards, NG, 2006) |
| "Anti-neoplastic treatment for acute lymphoblastic leukemia and age of disease did not influence body mass index and leptin level in the examined population." | ( Krawczuk-Rybak, M; Muszyńska-Rosłan, K; Sawicka-Zukowska, M; Topczewska, M, 2006) |
| "From 1981 to 1986, children with acute lymphoblastic leukemia (ALL) and initial WBC above 50,000/mm3, achieved significantly worse treatment results than children with lower WBC: over 6-year disease-free survival were respectively 33% and 60%." | ( Balcerska, A; Balwierz, W; Chybicka, A; Derwich, K; Dobaczewski, G; Juszczak, K; Kowalczyk, J; Krauze, A; Luszczyńska, A; Matysiak, M; Moryl-Bujakowska, A; Pawelec, K; Pawińska, K; Płoszyńska, A; Skoczeń, S; Sońta-Jakimczyk, D; Styczyńskii, J; Swiatkiewicz, V; Tomaszewska, R; Wachowiak, J; Wiśniewska-Slusarz, H; Wysocki, M, 2006) |
| "A 28-year-old woman with acute lymphoblastic leukemia developed fever and unilateral pleural based pulmonary infiltrate during prolonged chemotherapy induced neutropenia." | ( Salonen, JH, 2006) |
| "Children >/= 12 years, children with acute lymphoblastic leukemia, and children receiving radiotherapy or opiate analgesics were more likely to receive ADM by multivariate analysis." | ( Ahmad, N; Leavey, P; Portteus, A; Tobey, D, 2006) |
| "The Dana-Farber Cancer Institute (DFCI) Childhood ALL Consortium Protocol 95-01 was designed to minimize therapy-related morbidity for children with newly diagnosed ALL without compromising efficacy." | ( Asselin, B; Barr, R; Clavell, L; Cohen, HJ; Dalton, VK; Gelber, RD; Hurwitz, C; Levy, DE; Lipshultz, SE; Moghrabi, A; Neuberg, DS; Sallan, SE; Samson, Y; Schorin, M; Silverman, LB, 2007) |
| "The treatment of acute lymphoblastic leukemia (ALL) in children may cause sequelae, some appearing only at long-term follow-up." | ( Alves Aquino, C; Casulari, LA; Ferreira, M; Neves Mascarenhas, A; Oba, L; Papadia, C, 2006) |
| "We describe a case of acute lymphoblastic leukemia (ALL) treated with high-dose intravenous and intrathecal methotrexate combined with craniospinal RT resulting in DNL." | ( Ando, K; Ishikura, R; Kamikonya, N; Kaneda, Y; Nagami, Y; Nakao, N; Ogawa, M; Pande, AR; Tanizawa, T, 2006) |
| "In the study of 50 patients with childhood ALL treated according to the BFM-like protocol, it was found that even TPMT-heterozygous patients are at greater risk of thiopurine drug-related leukopenia (mean duration of period when children missed therapy as a result of leukopenia for TPMT-heterozygous patients was 11." | ( Dokmanovic, L; Janic, D; Jovanovic, N; Pavlovic, S; Petrucev, B; Tosic, N; Urosevic, J, 2006) |
| "In patients treated for acute lymphoblastic leukemia in childhood, the positive predictive values for statural deficit of both tests were low, except for the insulin-induced hypoglycemia test when a growth hormone peak <7 ng/mL was considered." | ( Barboza Filho, RF; Casulari, LA; Motta, LD; Naves, LA; Papadia, C; Suzuki, MT, 2006) |
| "Treatment-related toxicity in acute lymphoblastic leukemia (ALL) can not only be life threatening but may also affect relapse risk." | ( Cheng, C; Cook, EH; Das, S; Evans, WE; French, D; Frudakis, T; Hijiya, N; Kishi, S; Pei, D; Pui, CH; Relling, MV; Rizzari, C; Rosner, GL, 2007) |
| "The treatment given to children with acute lymphocytic leukemia has an important effect on their linear growth rate and nutritional status, and also on their serum copper levels." | ( Fisberg, M; Latorre, Mdo R; Sgarbieri, UR; Tone, LG, 2006) |
| "In childhood acute lymphoblastic leukemia (ALL), persistence of leukemic blasts during therapy is of crucial prognostic significance." | ( Hagemeier, C; Karawajew, L; Kirschner-Schwabe, R; Ludwig, WD; Moericke, A; Ratei, R; Rhein, P; Scheid, S; Schrappe, M; Seeger, K; Spang, R, 2007) |
| "We treated 26 patients with T-cell acute lymphoblastic leukemia (T-ALL) and 13 with T-cell lymphoblastic lymphoma (T-LBL) with nelarabine." | ( Appelbaum, FR; Coutre, SE; DeAngelo, DJ; Gockerman, JP; Johnson, JL; Larson, RA; Mitchell, BS; Stone, RM; Stopeck, AT; Yu, D, 2007) |
| "Ninety-seven consecutive patients with childhood ALL were studied prospectively by magnetic resonance imaging (MRI) of the lower extremities at the end of the treatment." | ( Harila-Saari, AH; Jartti, AE; Lanning, M; Möttönen, MI; Niinimäki, RA; Pääkkö, EL; Riikonen, PV; Seuri, RM, 2007) |
| "We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with intravenous acyclovir (ACV)." | ( Fujita, H; Iguchi, M; Ishigatsubo, Y; Ishizawa, J; Tachibana, T; Taguchi, J, 2007) |
| "Thirty-six untreated lymphoblastic lymphoma patients aged from 3 to 18 years were included, with 1 patient in stage II , 9 in stage III and 26 in stage IV." | ( Guan, ZZ; Huang, HQ; Li, YH; Ling, JY; Liu, DG; Sun, XF; Xia, Y; Xia, ZJ; Zhang, L; Zhen, ZJ; Zhou, ZM, 2007) |
| "Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) reveals very poor prognosis due to high incidence of relapse when treated with standard chemotherapy." | ( Hishida, A; Katagiri, T; Nakamura, Y; Naoe, T; Ohno, R; Sugiura, I; Takeuchi, J; Tsuruo, T; Usui, N; Yanada, M; Zembutsu, H, 2007) |
| "Survivors of childhood acute lymphoblastic leukemia (ALL) become obese, and are at increased risk for morbidity and mortality post therapy." | ( Bashore, L; Brooks, S; Church, TS; Dunn, AL; Eshelman, DA; Janiszewski, PM; Murray, JC; Oeffinger, KC; Ross, R; Sinclair, E; Turoff, AJ; Victor, RG, 2007) |
| "The treatment of acute lymphoblastic leukemia (ALL) often combines a neurotoxic chemotherapeutic protocol such as Berlin-Frankfurt-Munster-95 (BFM-95) with gentamicin, an antibiotic known to have an early and quickly reversed impact on olivocochlear reflex in animal studies." | ( Douniadakis, D; Ferekidis, E; Korres, S; Kosmidis, H; Psarommatis, I; Riga, M; Varvutsi, M; Yiotakis, I, 2007) |
| "A total of 121 children with acute lymphoblastic leukemia on HDMTX therapy were enrolled into this study." | ( Shi, S; Song, H; Tang, Y; Xu, W; Yang, S, 2007) |
| "Because Ph-positive acute lymphoblastic leukemia only responds transiently to imatinib therapy, we have used mouse models to test the efficacy of nilotinib against lymphoblastic leukemia caused by the P190 form of Bcr/Abl." | ( Feldhahn, N; Groffen, J; Heisterkamp, N; Kaur, P; Müschen, M; Pertz, V; Trageser, D; Zhang, B, 2007) |
| "Distinct clinicopathologic acute lymphoblastic leukemia (ALL) entities have been identified, resulting in the adoption of risk-oriented treatment approaches." | ( Thomas, X, 2007) |
| "We describe a 5-year-old boy with acute lymphoblastic leukemia in remission, in whom CBDC developed after treatment with trimethoprim/sulfamethoxazole (cotrimoxazole)." | ( Alli, N; Artüz, F; Kürekçi, E; Lenk, N; Oztaş, P; Polat, M, 2007) |
| "Our study included 37 patients with acute lymphoblastic leukemia (ALL) and 11 patients with Morbus Hodgkin (MH) disease, who were treated with high-dose glucocorticoid therapy, and 26 control patients with other types of malignancies." | ( Aschenbrenner, C; Baumgartner, M; Bieglmayer, C; Dworzak, M; Felder-Puig, R; Gadner, H; Koper, JW; Nasel, C; Ortner, M; Panzer-Grümayer, ER; Scherzer, C; Steinberger, K; Tissing, WJ; Topf, R; Voigtländer, T, 2007) |
| "The data of 329 children with acute lymphoblastic leukemia administering HDMTX in hospital were collected from 2003 to 2006." | ( Gu, J; Li, YZ; Lu, W; Zhang, CY, 2008) |
| "Treatment of childhood relapsed acute lymphoblastic leukemia (ALL) remains a significant challenge." | ( Borowitz, MJ; Camitta, BM; Carroll, WL; Devidas, M; Gaynon, PS; Hunger, SP; Linda, SB; Raetz, EA; Winick, NJ, 2008) |
| "The treatment of meningeal relapse in acute lymphoblastic leukemia (ALL) remains a challenging clinical problem." | ( Buffardi, S; Di Cesare-Merlone, A; Locatelli, F; Mangione, A; Marra, N; Menna, G; Misuraca, A; Parasole, R; Petruzziello, F; Poggi, V, 2008) |
| "To improve the outcome of children with acute lymphoblastic leukemia (ALL) treated at the National Cancer Institute, Bogota, Colombia, a protocol based on the BFM-90 (Berlin, Frankfurt, Munster study) and the LSA2L2 regimens was implemented in the year 1993." | ( Buendia, MT; Guevara, G; Lozano, JM; Saavedra, C; Suarez, GE, 2008) |
| "To achieve this goal, 36 children with acute lymphoblastic leukemia (24 females and 12 males) in the maintenance phase of therapy with 12 healthy children of matched age and sex served as a control group were recruited in this study." | ( Ahmed, MA; Al-Tonbary, YA; El-Chennawi, FA; Mossad, YM, 2008) |
| "Treatment failure in pediatric acute lymphoblastic leukemia (ALL) is related to cellular resistance to glucocorticoids (eg, prednisolone)." | ( Broekhuis, MJ; Den Boer, ML; Evans, WE; Holleman, A; Hulleman, E; Kazemier, KM; Pieters, R; Rudin, CM; VanderWeele, DJ, 2009) |
| "To describe a patient with Bcr-abl(+) acute lymphoblastic leukemia who developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) while being treated with high-dose imatinib." | ( Apostolidis, J; Charitaki, E; Harhalakis, N; Liapis, K; Nikiforakis, E; Panitsas, F, 2008) |
| "Despite advances in the treatment of acute lymphoblastic leukemia (ALL), the majority of children who relapse still die of ALL." | ( Baraz, R; Bendall, LJ; Bradstock, KF; Cisterne, A; Crazzolara, R; Hewson, J; Thien, M, 2009) |
| "Among 1614 children with acute lymphoblastic leukemia (ALL) treated with the Nordic Society for Paediatric Haematology and Oncology (NOPHO) ALL-92 protocol, 20 patients developed a second malignant neoplasm (SMN) with a cumulative risk of 1." | ( Al-Modhwahi, I; Andersen, MK; Behrendtz, M; Forestier, E; Hasle, H; Heyman, M; Kristinsson, J; Nersting, J; Nygaard, R; Schmiegelow, K; Svendsen, AL; Vettenranta, K; Weinshilboum, R, 2009) |
| "The standard management of childhood acute lymphoblastic leukemia with hyperleukocytosis is unclear and its treatment has focused on prompt leukocytoreduction." | ( Karakukcu, M; Kose, M; Ozdemir, MA; Patiroglu, T; Torun, YA, 2009) |
| "Treatment for childhood acute lymphoblastic leukemia (ALL) regularly includes the use of thiopurine drugs." | ( Cario, G; Coulthard, SA; Dördelmann, M; Eichelbaum, M; Kaatsch, P; Möricke, A; Reiter, A; Riehm, H; Schaeffeler, E; Schrappe, M; Schrauder, A; Schwab, M; Stanulla, M; Welte, K; Zimmermann, M, 2009) |
| "As a primary drug for the treatment of acute lymphoblastic leukemia (ALL), encapsulation of L-asparaginase (ASNase) into red blood cells (RBC) has been popular to circumvent immunogenicity from the exogenous protein." | ( Chung, HS; David, AE; Gitlin, SD; Kwon, YM; Moon, C; Park, YJ; Yang, VC; Yockman, J, 2009) |
| "Successful treatment of higher risk childhood ALL was associated with obesity, independent of cranial irradiation." | ( Hawks, RG; Meza, JL; Post-White, JE; Sacks, N; Seibel, NL; Smith, LM; Withycombe, JS, 2009) |
| "Patients with acute lymphoblastic leukemia (ALL), who develop antiasparaginase antibodies without clinical allergic reactions ("silent inactivation") during L: -asparaginase (L: -Asp) treatment, have poor outcomes." | ( Hasegawa, D; Hirabayashi, S; Hosoya, R; Inoue, T; Kizu, J; Machida, R; Manabe, A; Matsumoto, H; Miyake, K; Ogawa, C; Ohara, A; Watanabe, S; Yoshida, K, 2009) |
| "The treatment outcome of acute lymphoblastic leukemia (ALL) has improved steadily over the last 50 years." | ( Chen, GQ; Duan, XF; Wang, XD; Wu, YL; Xu, HZ; Yan, H; Zhao, M; Zhuang, HY, 2010) |
| "Acute lymphoblastic leukemia (ALL) with high-risk features has a poor prognosis in adults despite aggressive chemotherapy." | ( Forman, SJ; Kogut, NM; O'Donnell, MR; Palmer, JM; Senitzer, D; Slovak, ML; Snyder, DS; Spielberger, RT; Stein, AS; Thomas, SH; Tsai, NC, 2009) |
| "Significant progress in the treatment of acute lymphoblastic leukemia (ALL) has been achieved through more effective use of established drugs in risk-adapted treatment regimens." | ( Jeha, S, 2009) |
| "For the majority of children with acute lymphoblastic leukemia (ALL), CNS prophylaxis consists of either intrathecal (IT) methotrexate or triple IT therapy (ie, methotrexate with both cytarabine and hydrocortisone)." | ( Bostrom, B; Breiger, D; Brouwers, P; Chen, L; Dziura, J; Kadan-Lottick, NS; Kaleita, T; Neglia, JP; Nicoletti, M; Northrup, V; Stork, L, 2009) |
| "Methotrexate is a key drug in acute lymphoblastic leukemia (ALL) treatment; it inhibits DNA replication by blocking the conversion of 5,10 methylene tetrahydrofolate to 5-methylene tetrahydrofolate by methylene tetrahydrofolate reductase (MTHFR)." | ( Abdulghaffar, EE; Abou El Asrar, M; Adly, AA; El-Bostany, EA; El-Ghouroury, EA; Tantawy, AA, 2010) |
| "We report a child with acute lymphoblastic leukemia who developed primary cutaneous mucormycosis at the site of lumbar puncture during induction chemotherapy." | ( Arun, S; Kabra, SK; Sankar, J; Sankar, MJ; Seth, R; Thavraj, V; Vasantha, M, 2009) |
| "A total of 500 children with acute lymphoblastic leukemia treated according to the common Nordic treatment protocols were included, and we found that the RFC AA variant was associated with a 50% better chance of staying in remission compared with GG or GA variants (P = ." | ( Carlsen, N; Christensen, IJ; Dalhoff, K; Gregers, J; Lausen, B; Peterson, C; Rosthoej, S; Schmiegelow, K; Schroeder, H, 2010) |
| "Although the treatment outcome of acute lymphoblastic leukemia (ALL) has been improved in the past decades by combination chemotherapy, toxic side-effects of chemotherapeutics remain a major problem." | ( Brons, NH; Liao, Y; Liu, X; Lv, Y; Steinmetz, A; Sun, L; Wang, N; Wang, Q; Zheng, H, 2011) |
| "An 8-year-old male with acute lymphoblastic leukemia receiving chemotherapy, including intrathecal methotrexate, presented to our emergency center with 2 hours of expressive aphasia and flaccid right hemiplegia." | ( El-Hakam, LM; Illner, A; Ramocki, MB; Riviello, JJ, 2010) |
| "Adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma were randomized to receive, as part of their induction therapy on days 1-8 and 15-22, either dexamethasone 8 mg/m(2) or prednisolone 60 mg/m(2)." | ( Amadori, S; Berneman, Z; Bron, D; De Bock, R; de Witte, T; Feremans, W; Fillet, G; Gilotay, C; Jaksic, B; Labar, B; Marie, JP; Mistrik, M; Muus, P; Nemet, D; Sinnige, H; Suciu, S; Vreugdenhil, G; Willemze, R, 2010) |
| "The multicenter trial ALL-REZ BFM (ie, Acute Lymphoblastic Leukemia Relapse Berlin-Frankfurt-Münster) 90 was designed to improve prognosis for children with relapsed acute lymphoblastic leukemia (ALL) by time-to-relapse- and site-of-relapse-adapted stratification and by introduction of novel chemotherapy elements and to evaluate new prognostic parameters in a large, population-based cohort." | ( Ebell, W; Escherich, G; Fengler, R; Henze, G; Karachunsky, A; Kaspers, G; Klingebiel, T; Mann, G; Niggli, F; Ratei, R; Schrappe, M; Tallen, G; von Stackelberg, A, 2010) |
| "In a group of newly diagnosed acute lymphocytic leukemia (ALL) children we evaluated a number of hemostatic and inflammatory markers at diagnosis and at different time points during chemotherapy for the remission induction to identify alterations in the plasma levels of prothrombotic markers before and during the course of chemotherapy." | ( Altomare, M; Crescenzio, N; De Mattia, D; Del Vecchio, GC; Falanga, A; Giordano, P; Marchetti, M; Molinari, AC; Perutelli, P; Russo, G; Santoro, N; Saracco, P, 2010) |
| "Pediatric acute lymphoblastic leukemia (ALL) represents one of the best examples of progress in disease treatment and improved outcome based in part upon the incorporation of the principles of pharmacogenomics." | ( Meeker, ND; Schiffman, JD; Yang, JJ, 2010) |
| "A 4-year-old boy with acute lymphoblastic leukemia (ALL) was inserted a central venous catheter into right vena jugularis interna, whereas on BFM-ALL (Protocol 1) therapy." | ( Akyay, A; Bçakç, Z; Cetin, II; Olcay, L; Oztürkmen, S; Paç, A; Polat, TB; Senayl, A, 2010) |
| "A total of 201 pediatric cases of acute lymphoblastic leukemia were treated with the ALL-96 protocol by the Kyushu-Yamaguchi Children's Cancer Study Group." | ( Fujita, K; Hidaka, Y; Hotta, N; Inada, H; Itonaga, N; Kawakami, K; Kawano, Y; Matsuzaki, A; Moritake, H; Nagatoshi, Y; Nakayama, H; Okamura, J; Suminoe, A; Ueda, K; Yamanaka, T; Yanai, F, 2010) |
| "The standard treatment protocol for acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) in childhood includes intravenous therapy with asparaginase (Asp), which may cause hyperammonemia." | ( Beblo, S; Bierbach, U; Jörck, C; Kiess, W; Mütze, U; Weigel, JF, 2011) |
| "Currently, treatment of childhood acute lymphoblastic leukemia (ALL) includes cytarabine, especially in high-risk patients." | ( Apibal, S; Banklau, C; Hongeng, S; Jindadamrongwech, S; Paisooksantivatana, K; Pakakasama, S; Sawangpanich, R, 2010) |
| "This is especially true in children with acute lymphoblastic leukemia (ALL) in whom the metabolic syndrome may begin during therapy, demanding clarification of the trajectory of weight gain so that effective interventions may be developed." | ( Barr, RD; Collins, L; Nayiager, T; Pollock, BH; Zarzabal, LA, 2010) |
| "Children with acute lymphoblastic leukemia (ALL) routinely receive blood transfusions during therapy, although few studies to date have quantified transfusion-related iron burden in these patients." | ( Eng, J; Fish, JD, 2011) |
| "We report a child with acute lymphoblastic leukemia who developed brain abscesses caused by Acanthamoeba during induction therapy." | ( Benesch, M; Lackner, H; Maritschnegg, P; Nebl, A; Schwinger, W; Sovinz, P; Urban, C; Walochnik, J, 2011) |
| "Herein, we report a 14-year-old boy with acute lymphoblastic leukemia who was receiving chemotherapy for induction with vincristine, idarubicin, L-asparaginase, and prednisolone, presented with typical varicella skin lesions and varicella-zoster virus was detected in his serum by real-time polymerase chain reaction (PCR)." | ( Cheng, SN; Fan, HC; Lu, YC; Wang, CC, 2011) |
| "A 10-year-old boy with high-risk acute lymphoblastic leukemia treated with hematopoietic stem-cell transplantation developed pulmonary aspergillosis while receiving prophylactic voriconazole." | ( Bierings, MB; Melchers, WJ; Thors, VS; Verweij, PE; Wolfs, TF, 2011) |
| "We investigated whether age, race, sex, acute lymphoblastic leukemia treatment arm, body mass, serum lipids, albumin and cortisol levels, dexamethasone pharmacokinetics, and genome-wide germline genetic polymorphisms were associated with symptomatic osteonecrosis." | ( Cai, X; Cheng, C; Evans, WE; Howard, SC; Kaste, SC; Kawedia, JD; Neale, G; Panetta, JC; Pei, D; Pui, CH; Relling, MV, 2011) |
| "Eleven children with acute lymphoblastic leukemia were assessed at 7 time points (6-mo intervals) from diagnosis to 1 year after the completion of therapy." | ( Barr, R; Morrison, J; Nayiager, T; Sala, A; Webber, CE, 2011) |
| "A 4-year-old boy with acute lymphoblastic leukemia who was receiving 6-mercaptopurine during the maintenance chemotherapy experienced prolonged generalized tonic nocturnal seizures because of severe hypoglycemia after his evening dose by a 12-hour period of fasting." | ( Dabbagh, O; El-Bitar, MK; Muwakkit, SA, 2011) |
| "Acute lymphoblastic leukemia (ALL), the most common form of childhood cancer, usually responds to chemotherapy but patients who develop disease relapse have a poor prognosis." | ( Bendall, LJ; Bradstock, KF; Hewson, J; Wallington-Beddoe, CT, 2011) |
| "BU used to treat patients with acute lymphoblastic leukemia (ALL)." | ( Chen, YB; Hu, J; Shen, ZX; Tang, W; Wang, L; Zhao, WL, 2011) |
| "Seventy-two childhood ALL survivors treated with chemotherapy alone underwent a neurocognitive battery consisting of: Trail Making Tests A (TMTA) and B (TMTB), Grooved Pegboard Test Dominant-Hand and Nondominant-Hand, Digit Span subtest, and Verbal Fluency Test." | ( Bondy, M; Brouwers, P; Dreyer, Z; El-Zein, RA; Etzel, CJ; Harris, LL; Holm, S; Kamdar, KY; Krull, KR; Okcu, MF; Potter, BS; Scaglia, F, 2011) |
| "We report a 26-year-old male with acute lymphoblastic leukemia who developed cutaneous aspergillosis after undergoing combined immunosuppressive treatment including corticosteroid, cyclosporine A, mychophenolate mofetil and mesenchymal stem cells for steroid refractory skin acute graft versus host disease after myeloablative haematopoietic stem cell transplantation." | ( Aki, ŞZ; Akyürek, N; Şenol, E; Sucak, G; Tunçcan, ÖG, 2011) |
| "Patients with acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), or Burkitt lymphoma (BL) who were receiving frontline myelosuppressive chemotherapy were randomized to receive epoetin alpha or no epoetin during the first 6 cycles of their planned chemotherapy." | ( Bekele, BN; Bruera, E; Cabanillas, ME; Cortes, JE; Foudray, MC; Kantarjian, H; Mattiuzzi, GN; Rytting, ME; Thomas, DA; Xiao, L, 2012) |
| "Treatment regimens for childhood acute lymphoblastic leukemia (ALL) contain neurotoxic agents that may interfere with neuromuscular health." | ( Green, DM; Huang, TT; Hudson, MM; Krull, KR; Morris, EB; Ness, KK; Pui, CH; Robison, LL, 2012) |
| "Children with acute lymphoblastic leukemia (ALL) recive high doses of glucocorticosteroid as part of their treatment." | ( Andersen, EW; Hjalgrim, H; Juul, A; Kvist, TK; Lausen, B; Lausten-Thomsen, U; Schmiegelow, K; Vestergaard, TR, 2011) |
| "Treatment of childhood ALL with 0-10 g/m(2) of cyclophosphamide and cranial irradiation does not affect fertility or semen quality but may impair long-term Leydig cell function." | ( Cooper, TG; Heikkinen, R; Henriksson, M; Jahnukainen, K; Mäkitie, O; Puukko-Viertomies, LR, 2011) |
| "Children with lymphoblastic lymphoma on induction chemotherapy protocols including very high doses of corticosteroids transiently demonstrated altered FDG uptake patterns, including increased superficial facial uptake and reduced hepatic uptake." | ( Absalon, MJ; Gelfand, MJ; Sharp, SE, 2012) |
| "Causes of treatment failure in acute lymphoblastic leukemia (ALL) are still poorly understood." | ( Haus, O; Jarzab, B; Jarzab, M; Kowalska, M; Oczko-Wojciechowska, M; Pogorzala, M; Styczynski, J; Szczepanek, J; Tretyn, A; Wysocki, M, 2012) |
| "In acute lymphoblastic leukemia (ALL) patients, the bone marrow niche is widely known to be an important element of treatment response and relapse." | ( Adachi, S; Fujino, H; Heike, T; Hiramatsu, H; Ishikawa, F; Ito, M; Kato, I; Morita, M; Nakahata, T; Nishinaka, Y; Niwa, A; Saito, MK; Umeda, K, 2011) |
| "All these children [3 acute lymphoblastic leukemia and 5 acute myeloid leukemia (AML) cases] were receiving chemotherapy during the course of infection, except 1 who was found to be H1N1 positive at the same time that she was diagnosed with AML." | ( Azik, F; Culha, V; Kara, A; Tavil, B; Tezer, H; Tunç, B; Yaral, N, 2012) |
| "The aim of this study was (1) to treat childhood ALL with a protocol that would have reduced use of cranial irradiation and containing infusions of high-dose methotrexate HDMTX (5 g/m(2)) without compromising on survival, and (2) evaluate the experience with HDMTX in a tertiary care cancer centre in a developing country." | ( Abedin, S; Kapoor, G; Sinha, R, 2012) |
| "We also show that acute lymphoblastic leukemia patients undergoing 6-MP treatment display a VNTR architecture-dependent response to 6-MP." | ( Dokmanovic, L; Georgitsi, M; Janic, D; Kassela, K; Klaassen, K; Kotur, N; Krstovski, N; Leontari, I; Nikcevic, G; Patrinos, GP; Pavlovic, S; Radmilovic, M; Simeonidis, A; Sivolapenko, G; Stankovic, B; Stojiljkovic, M; Vicha, A; Zukic, B, 2012) |
| "We examined six patients treated for acute lymphoblastic leukemia (ALL) with chemotherapy alone, with suspicious central hypothyroidism (CH)." | ( Baronio, F; Battisti, L; Radetti, G, 2011) |
| "The backbone of drug therapy used in acute lymphoblastic leukemia (ALL) in children includes 6-mercaptopurine (6-MP)." | ( Adam de Beaumais, T; Jacqz-Aigrain, E, 2012) |
| "Therapeutic options for advanced B-cell acute lymphocytic leukemia are still limited and acquired drug resistance and extramedullary tissue infiltration are two major obstacles during treatment." | ( Barbieri, O; Benelli, R; Carlone, S; Ciarlo, M; Ferrari, N; Venè, R, 2012) |
| "Acute lymphoblastic leukemia (ALL) is the most common malignancy affecting children accounting for approximately 30% of childhood cancers, which was uniformly fatal before the advent of effective chemotherapy." | ( Ribatti, D, 2012) |
| "Patients treated for childhood acute lymphoblastic leukemia (ALL) are considered to be at increased risk of developing second neoplasm." | ( Debeljak, M; Dolžan, V; Erčulj, N; Faganel Kotnik, B; Jazbec, J, 2012) |
| "Although the outcome of patients with acute lymphoblastic leukemia (ALL) has been improved continuously by chemotherapy and tyrosine kinase inhibitors, prognosis of patients with Philadelphia chromosome positive (Ph(+)) ALL still remains poor." | ( Arndt, S; Henze, G; Kalies, K; Köchling, J; Marschke, C; Rott, Y; Schmidt, M; Westermann, J; Wittig, B, 2012) |
| "ADMA is elevated in adult childhood ALL survivors, which can reflect late detrimental chemotherapy effects, partially related to minor lipid profile changes." | ( Balwierz, W; Ćwiklińska, M; Grodzicki, TK; Gryglewska, B; Kwater, A; Strach, M; Sulicka, J; Surdacki, A, 2012) |
| "Acute lymphoblastic leukemia (ALL) cells treated with drugs can become drug-tolerant if co-cultured with protective stromal mouse embryonic fibroblasts (MEFs)." | ( Arutyunyan, A; Fei, F; Feldhahn, N; Groffen, J; Groffen, P; Heisterkamp, N; Lim, M; Stoddart, S; Yi, SJ, 2012) |
| "Treatment of acute lymphoblastic leukemia (ALL) has included the use of prophylactic cranial irradiation in up to 20% of children with high-risk disease despite known cognitive risks of this treatment modality." | ( Cheng, C; Conklin, HM; Krull, KR; Pei, D; Pui, CH; Reddick, WE, 2012) |
| "We describe a 5-year-old female with acute lymphoblastic leukemia (ALL) who suffered from cytomegalovirus (CMV) retinitis during maintenance therapy consisting of 6-mercaptopurine (6-MP) and methotrexate (MTX) with pulses of vincristine (VCR) and dexamethasone (DEX)." | ( Harada, M; Kamimura, S; Kojima, H; Moritake, H; Nao-I, N; Nunoi, H; Shimonodan, H; Sugimoto, T, 2013) |
| "Acute lymphoblastic leukemia (ALL) and its treatment may adversely affect kidney function." | ( Birkenfeld, B; Brodkiewicz, A; Listewnik, MH; Matacz, M; Peregud-Pogorzelski, J; Piwowarska-Bilska, H; Szychot, E; Zorga, P, 2011) |
| "A child suffering from acute lymphoblastic leukemia on treatment with exclusive chemotherapy presented with vision-threatening cytomegalovirus (CMV) retinitis in 1 eye." | ( Bhalekar, S; Jain, R; Singh, R; Trehan, A, 2013) |
| "Children younger than 18 years with acute lymphoblastic leukemia or lymphoma scheduled to undergo chemotherapy were randomized to receive oral ciprofloxacin 20mg/kg/day or placebo from the beginning of their chemotherapy." | ( Chelae, S; Khwanna, T; Laoprasopwattana, K; Sujjanunt, T; Suwankeeree, P; Tunyapanit, W, 2013) |
| "The high inter-individual variability of acute lymphoblastic leukemia responses to glucocorticoids suggest that either patients should be selected for prednisone or dexamethasone treatment on the basis of predictive biomarkers or that prednisone should be used directly in combination with a very low and safe dose of dexamethasone to potentiate its antileukemic activity." | ( Blazek, B; Bubanska, E; Burianova, R; Dzubak, P; Hajduch, M; Hak, J; Kaiserova, E; Konecny, P; Mihal, V; Novak, Z; Pospisilova, D; Radova, L; Salkova, S; Spenerova, M; Srovnal, J; Stary, J; Timr, P; Votava, T, 2014) |
| "Two children with acute lymphoblastic leukemia/lymphoma developed recurrent acute pancreatitis during treatment; the etiology was presumed to be secondary to 6-mercaptopurine (6MP)." | ( Alkayed, K; Bazzeh, F; Halalsheh, H; Madanat, F; Salami, K, 2013) |
| "Acute lymphoblastic leukemia (ALL) maintenance therapy (MT) has been occasionally associated with symptomatic hypoglycemia (SH), attributed to purine analog (mercaptopurine [6-MP])." | ( Aledo, A; Brar, PC; Franklin, BH; Visavachaipan, N, 2013) |
| "Chemo- and radiotherapy used in acute lymphoblastic leukemia (ALL) can influence on brain functioning in the future." | ( Braszko, J; Grabowska, A; Holownia, A; Krawczuk-Rybak, M; Muszynska-Roslan, K; Protas, PT, 2012) |
| "Children with acute lymphoblastic leukemia experience musculoskeletal morbidity during therapy." | ( Barr, RD; Nayiager, T; Rayar, M; Sala, A; Webber, CE, 2013) |
| "Although survival rates for acute lymphocytic leukemia (ALL), especially in children, have shown dramatic improvement over time, poor outcomes are still observed in patients who have refractory or relapsed disease after conventional chemotherapy." | ( Chen, Q; Du, XL, 2013) |
| "Acute lymphoblastic leukemia is still an incurable disease with resistance to therapy developing in the majority of patients." | ( Jimenez-Del-Rio, M; Mendivil-Perez, M; Velez-Pardo, C, 2012) |
| "Adult patients with acute lymphoblastic leukemia frequently relapse or are refractory to conventional treatments." | ( Harrison, TS; Lyseng-Williamson, KA, 2013) |
| "Children with acute lymphoblastic leukemia (ALL) undergo multiple lumbar punctures (LPs) during their course of treatment for diagnostic and therapeutic purposes." | ( Attinà, G; Chiaretti, A; Coccia, P; Maurizi, P; Riccardi, R; Rizzo, D; Ruggiero, A; Russo, I, 2014) |
| "Children with acute lymphoblastic leukemia (ALL) and high minimal residual disease (MRD) levels after initial chemotherapy have a poor clinical outcome." | ( Alvaro, F; Bierings, MB; Cross, S; Dalla Pozza, L; de Bont, ES; de Groot-Kruseman, HA; de Haas, V; Haber, M; Hoogerbrugge, PM; Kaspers, GJ; Law, T; Maarten Egeler, R; Marshall, GM; Mueller, H; Ng, A; Norris, MD; Pieters, R; Révész, T; Suppiah, R; Sutton, R; van den Berg, H; van der Schoot, E; van der Velden, VH; van Dongen, J; Venn, NC, 2013) |
| "We report a toddler with acute lymphoblastic leukemia who acquired rhino-orbital mucormycosis caused by Rhizopus species at the end of induction chemotherapy." | ( Almannai, M; Estrada, B; Imran, H; Siddiqui, AH, 2013) |
| "A 5-year-old girl with precursor B-cell acute lymphoblastic leukemia developed peripheral-type right facial palsy and very faint erythema on her right pinna during maintenance therapy." | ( Hashiguchi, S; Kawano, Y; Kodama, Y; Kurauchi, K; Nishi, J; Nishikawa, T; Okamoto, Y; Shinkoda, Y; Suda, Y; Tanabe, T; Yamaki, Y, 2013) |
| "Acute lymphoblastic leukemia (ALL) and its treatment may lead to impairment of kidney function." | ( Birkenfeld, B; Brodkiewicz, A; Listewnik, MH; Matacz, M; Peregud-Pogorzelski, J; Piwowarska-Bilska, H; Szychot, E; Zorga, P, 2012) |
| "Among children diagnosed with acute lymphoblastic leukemia (ALL) and given chemotherapy-only treatment, 40% to 70% of survivors experience neurocognitive impairment." | ( Bisen-Hersh, EB; Hineline, PN; Walker, EA, 2013) |
| "We describe a 42-year-old woman with acute lymphoblastic leukemia who was treated with chemotherapy consisting of intrathecal MTX who developed a progressive myelopathy." | ( Diong, CP; Gosavi, T; Lim, SH, 2013) |
| "A patient with acute lymphoblastic leukemia who was hypersensitive to native Escherichia coli L-asparaginase (L-asp) underwent readministration of the L-asp without serious adverse effects for 11 doses using a desensitization protocol every time." | ( Fukuda, T; Hayase, T; Kashii, Y; Kawahara, Y; Momoi, MY; Morimoto, A, 2014) |
| "The treatment of acute lymphoblastic leukemia (ALL) in childhood and adolescence achieves nowadays cure rates of more than 80%." | ( Bartram, CR; Koehler, R, 2013) |
| "In the ALL-BFM studies for treatment of acute lymphoblastic leukemia, reduction of leukemic blasts in peripheral blood after a one-week prednisone pre-phase - the so-called prednisone response - has been used for risk stratification since the 1980s and has been one of the most relevant factors for identification of high-risk patients." | ( Attarbaschi, A; Beier, R; Lauten, M; Möricke, A; Niggli, F; Odenwald, E; Schrappe, M; Stanulla, M; Zimmermann, M, 2013) |
| "Drug resistance in acute lymphoblastic leukemia (ALL) remains a major problem warranting new treatment strategies." | ( Conway, EM; Crispino, J; Gang, EJ; Hsieh, YT; Huantes, S; Kahn, M; Kim, YM; Klemm, L; McMillan, M; Mullighan, CG; Müschen, M; Naing, K; Nguyen, C; Park, E; Pelus, LM; Pham, J; Swaminathan, S; Zhao, Y, 2014) |
| "Dexamethasone is used in acute lymphoblastic leukemia (ALL) treatment, though long-term impact on central nervous system (CNS) function is unclear." | ( Brinkman, TM; Edelmann, MN; Hudson, MM; Krull, KR; Ogg, RJ; Pui, CH; Robison, LL; Sabin, ND; Scoggins, MA; Srivastava, DK, 2013) |
| "Treatment of acute lymphoblastic leukemia is unsatisfactory in adults due to disease and patient-related factors and probably because adult chemotherapy regimens are weaker than pediatric protocols." | ( Acar, K; Aksu, S; Atay, H; Bektas, O; Buyukasik, Y; Goker, H; Haznedaroglu, IC; Kelkitli, E; Ozcebe, OI; Ozdemir, E; Pamukcuoglu, M; Sayınalp, N; Serefhanoglu, S; Sucak, GT; Turgut, M; Uz, B; Yagci, M, 2013) |
| "The immune system of children with acute lymphoblastic leukemia (ALL) is affected by both the underlying disease and the chemotherapy." | ( Bertolizio, G; Biondi, A; D'Amico, G; Dander, E; Ingelmo, PM; Jankovic, M; Sahillioglu, E; Somaini, M; Stucchi, R, 2013) |
| "We reviewed patients with acute lymphoblastic leukemia treated with corticosteroids and asparaginase who received metformin for control of hyperglycemia." | ( Bostrom, B; Chu, J; Gandrud, L; McEvoy, R; Messinger, Y; Uppal, P, 2013) |
| "Fifteen pediatric patients with acute lymphoblastic leukemia and one patient with Burkitt lymphoma, with a total of 26 treatment courses of HD-MTX, were enrolled." | ( Adachi, S; Heike, T; Kubota, M; Nakata, R; Shima, M; Takeshita, Y; Watanabe, K, 2014) |
| "The event-free survival of childhood acute lymphoblastic leukemia (ALL) has been reported to be superior when oral methotrexate (MTX) and 6-mercaptopurine (6MP) maintenance therapy (MT) is administered in the evening compared to the morning." | ( Christensen, RH; Clemmensen, KK; Harila-Saari, A; Heyman, M; Jonsson, OG; Rosthøj, S; Schmiegelow, K; Shabaneh, DN; Wesenberg, F, 2014) |
| "Hyper-CVAD is widely used to treat acute lymphoblastic leukemia (ALL) and aggressive lymphomas." | ( Ahlberg, L; Amini, RM; Åström, M; Bernell, P; Hägglund, H; Hallböök, H; Hulegårdh, E; Karlsson, K; Kozlowski, P; Markuszewska-Kuczymska, A; Smedmyr, B; Tomaszewska-Toporska, B, 2014) |
| "Acute lymphoblastic leukemia patients after being treated with methotrexate, have differences in methotrexate serum levels and toxic side effects." | ( Ansari, S; Bahoush, G; Rafsanjani, KA; Sharafi, H; Sharifi, MJ; Zaker, F, 2014) |
| "Pediatric patients with acute lymphoblastic leukemia (ALL) are treated with oral 6-mercaptopurine (6MP) for nearly 2 years, but no pediatric formulation has been available." | ( Hanff, LM; Mathot, RA; Pieters, R; Postma, DJ; Ramnarain, S; Smeets, O; Vermes, A; Zwaan, CM, 2014) |
| "Pediatric acute lymphoblastic leukemia (ALL) is treated with combination chemotherapy including mercaptopurine (6MP) as an important component." | ( Barcelos, A; Bökkerink, JP; Brouwer, C; Cloos, J; De Abreu, R; de Groot-Kruseman, H; de Haas, V; Dubbelman, B; Jansen, G; Kaspers, GL; Peters, GJ; Wojtuszkiewicz, A, 2014) |
| "This study included 127 Lebanese acute lymphoblastic leukemia patients, of whom 117 were treated following the St Jude's Children Research Hospital protocol." | ( Abboud, MR; Akra-Ismail, M; Aridi, C; Mahfouz, R; Muwakkit, SA; Solh, H; Zgheib, NK, 2014) |
| "We examined 57 survivors of childhood ALL, who were off treatment for at least 2 years and were in remission, aged 4-18 years, and 221 unrelated healthy controls." | ( Hamidah, A; Jamal, R; Loh, CK; Ratnam, VC; Sham Marina, M; Tamil, AM; Tuti Iryani, MD; Zarina, LA, 2014) |
| "We report an infant with acute lymphoblastic leukemia who developed disseminated adenovirus infection while lymphopenic during maintenance chemotherapy 6 months following a bout of adenoviral diarrhea." | ( Alcamo, AM; Grimley, MS; Mo, JQ; O'Brien, MM; Pinchasik, DE, 2015) |
| "Acute lymphoblastic leukemia (ALL) arises due to several genetic alterations in progenitor cells, and methotrexate is frequently used as part of the treatment regimen." | ( Bellampalli, R; Bhaskaranand, N; Bhat, KG; Guruprasad, KP; Phani, NM; Prasad, K; Rai, PS; Satyamoorthy, K, 2015) |
| "Treatment of mice with acute myeloid or lymphoblastic leukemia with a pharmacologic inhibitor of the synthesis of duodenal serotonin, a hormone suppressing osteoblast numbers, inhibited loss of osteoblasts." | ( Berman, E; Bhagat, G; Dempster, DW; Dougall, W; Economides, AN; Galan-Diez, M; Galili, N; Kalajzic, I; Kode, A; Kousteni, S; Krevvata, M; Manavalan, JS; Matthews, BG; Mukherjee, S; Nickolas, TL; Park, D; Raza, A; Silva, BC; Teruya-Feldstein, J; Zhang, CA, 2014) |
| "A group of 87 patients with acute lymphoblastic leukemia treated in the Department of Pediatric Oncology and Hematology in Krakow was enrolled to the study." | ( Balwierz, W; Czogała, M; Rogatko, I; Sztefko, K, 2014) |
| "Five-year survival from childhood acute lymphoblastic leukemia (ALL) approaches 90%, but 40% of survivors experience central nervous system (CNS) treatment-related cognitive problems." | ( Gundy, P; Hockenberry, MJ; Ki Moore, IM; Koerner, KM; McCarthy, K; Montgomery, DW; Pasvogel, A; Taylor, OA, 2015) |
| "Acute lymphoblastic leukemia (ALL) and chemotherapy can cause immune imbalance, and gaseous molecule hydrogen sulfide (H2S) can participate in the process of immune response." | ( Du, J; Du, S; Geng, B; Jia, Y; Jin, H; Sun, L; Sun, Y; Tang, C; Tang, H; Wu, W, 2014) |
| "BH3 mimetic drugs may be useful to treat acute lymphoblastic leukemia (ALL) but the sensitivity of primary tumor cells has not been fully evaluated." | ( Alford, SE; Chambers, TC; Eichhorn, JM; Falkenburg, JH; Goselink, HM; Jedema, I; Kothari, A; Loeff, FC; Sakurikar, N; Saylors, RL, 2015) |
| "The cost to a family with a child with acute lymphoblastic leukemia (ALL) during the first month of therapy was analyzed." | ( Bansal, D; Ghatak, N; Trehan, A, 2016) |
| "The identification of childhood acute lymphoblastic leukemia (ch-ALL) patients who are at a higher risk of chemotherapy resistance and relapse is essential for successful treatment decisions, despite the application of novel therapies." | ( Anastasiou, T; Avgeris, M; Baka, M; Gourgiotis, D; Kosmidis, H; Piatopoulou, D; Scorilas, A; Stamati, L, 2015) |
| "The outcome of childhood acute lymphoblastic leukemia has improved because of intensive chemotherapy and supportive care." | ( Baytan, B; Evim, MS; Güler, S; Güneş, AM; Okan, M, 2015) |
| "Information about fusion transcripts in acute lymphoblastic leukemia (ALL) is used to risk-stratify patients, decide on the treatment and to detect minimal residual disease." | ( Bakhshi, S; Chopra, A; Dwivedi, R; Gogia, A; Kumar, D; Kumar, L; Kumar, R; Seth, R; Soni, S; Verma, D; Vishwakama, G; Vishwanathan, A, 2015) |
| "TPMT gene expression was determined in childhood ALL patients at diagnosis (n = 57) and during the maintenance therapy (n = 27)." | ( Dokmanovic, L; Janic, D; Katsila, T; Kotur, N; Krstovski, N; Patrinos, GP; Pavlovic, S; Stankovic, B; Tosic, N; Zukic, B, 2015) |
| "In acute lymphoblastic leukemia (ALL) the bone marrow microenvironment provides growth and survival signals that may confer resistance to chemotherapy." | ( DiPersio, JF; Fletcher, TR; Hsu, YM; Link, DC; Schmidt, AP; Stock, W; Trinkaus, KM; Uy, GL; Westervelt, P, 2015) |
| "Outcome of children with acute lymphoblastic leukemia (ALL) has improved over the years, but not for those with multiple recurrences because of high therapy resistance and heavily pretreated history that potentially cause physical damages." | ( Aoki, Y; Imai, K; Ishiwata, Y; Kajiwara, M; Miyawaki, R; Mizutani, S; Morio, T; Takagi, M; Tomizawa, D; Yasuhara, M, 2016) |
| "Induction therapy for childhood acute lymphoblastic leukemia (ALL) traditionally includes prednisone; yet, dexamethasone may have higher antileukemic potency, leading to fewer relapses and improved survival." | ( Aricò, M; Attarbaschi, A; Barisone, E; Bartram, CR; Basso, G; Beier, R; Biondi, A; Caruso, R; Cazzaniga, G; Conter, V; Greiner, J; Harbott, J; Kremens, B; Kulozik, AE; Lo Nigro, L; Locatelli, F; Mann, G; Möricke, A; Niggli, F; Parasole, R; Ratei, R; Rössig, C; Schrappe, M; Silvestri, D; Stanulla, M; Valsecchi, MG; von Stackelberg, A; Zimmermann, M, 2016) |
| "The cure rate of pediatric acute lymphoblastic leukemia (ALL) has significantly improved in the past thirty years, however not all patient cohorts respond well to current chemotherapy regimens." | ( Gautam, LN; Lang, W; Ling, T; Rivas, F, 2016) |
| "Treatment resistance in acute lymphoblastic leukemia (ALL) is often caused by defects in programmed cell death, e." | ( Fulda, S; Gerges, S; Rohde, K, 2016) |
| "Survivors of childhood acute lymphoblastic leukemia treated on contemporary chemotherapy-only protocols demonstrate executive dysfunction." | ( Brinkman, TM; Cheung, YT; Fellah, S; Hudson, MM; Kimberg, C; Krull, KR; Liu, W; Ogg, R; Pui, CH; Reddick, WE; Robison, LL; Srivastava, D, 2016) |
| "Children with relapsed acute lymphoblastic leukemia (ALL) typically receive vincristine-prednisone-L-asparaginase-doxorubicin reinduction chemotherapy similar to contemporary induction regimens." | ( Fu, CH; Gaynon, PS; Sun, W; Wayne, AS; Yeo, KK, 2016) |
| "We present a case of acute pre-T-lymphoblastic leukemia in a Jehovah's Witness who did not accept blood transfusion during chemotherapy." | ( Bliźniewska, K; Chojnowski, K; Janus, A; Robak, M; Treliński, J, 2016) |
| "Survival for childhood acute lymphoblastic leukemia (ALL) has improved significantly, but these benefits may not be available to many children from low and middle income countries, where reasons for treatment failure may be unique to their environment." | ( Ashraf, MS; Belgaumi, AF; Iftikhar, S; Jabeen, K, 2016) |
| "Relapse in pediatric T-cell acute lymphoblastic leukemia (T-ALL) remains a significant clinical problem and is thought to be associated with clonal selection during treatment." | ( Anderson, D; Beesley, AH; Bendak, K; Cole, CH; Kees, UR; Lock, RB; Marshall, GM; Samuels, AL; Sutton, R; Venn, NC; Wells, JE; Yadav, BD, 2016) |
| "Patients ages 1 to 17 years with acute lymphoblastic leukemia (ALL) were treated according to modified ALL Intercontinental Berlin-Frankfurt-Münster (IC-BFM) 2002 protocol." | ( Antillón, FG; Blanco, JG; Borrayo, DA; Castellanos, M; Conter, V; Garrido, CP; Girón, V; Letona, TR; Lorenzana, R; Mack, RA; Melgar, MA; Metzger, M; Osorio, EJ; Ribeiro, RC; Rossi, E; Valsecchi, MG; Valverde, PD, 2017) |
| "Advances in acute lymphocytic leukemia (ALL) therapy has led to long-term survival rates in children." | ( Le Jeune, C; Thomas, X, 2016) |
| "Recent studies in children with acute lymphoblastic leukemia have conclusively demonstrated that nonadherence to oral antimetabolite therapy is associated with a significant increase in relapse risk." | ( Bhatia, S; Gupta, S, 2017) |
| "T-cell acute lymphoblastic leukemia (ALL) and lymphoma (LBL) are aggressive hematologic neoplasms that are treated with combination chemotherapy in the frontline, but have limited options in the relapsed or refractory setting." | ( Gandhi, V; Kadia, TM, 2017) |
| "Survivors of childhood ALL aged 4-18 years who had completed chemotherapy for 2 years or more were evaluated for VIPN using both the clinical Total Neuropathy Score (cTNS) and nerve conduction studies." | ( Ariffin, H; Fong, CY; Goh, KJ; Lee, VWM; Ong, LC; Tay, CG, 2017) |
| "Adolescents with acute lymphoblastic leukemia (ALL) develop osteopenia early in therapy, potentially exacerbated by high rates of concurrent Vitamin D deficiency." | ( Butturini, AM; Freyer, DR; Gilsanz, V; Mittelman, SD; Mueske, NM; Orgel, E; Sposto, R; Wren, TAL, 2017) |
| "We describe a case of acute lymphoblastic leukemia in which PRES developed secondary to hyponatremia despite being normotensive during receipt of chemotherapy." | ( Bahadir, A; Erduran, E; Eroglu, N, 2017) |
| "Outcome in childhood acute lymphoblastic leukemia is prognosticated from levels of minimal residual disease after remission induction therapy." | ( Bourquin, JP; Dempsey, C; Krishnan, S; McGinn, OJ; Saha, V; Sapra, P; Stern, PL, 2017) |
| "Pediatric acute lymphoblastic leukemia (ALL) affects a substantial number of children every year and requires a long and rigorous course of chemotherapy treatments in three stages, with the longest phase, the maintenance phase, lasting 2-3years." | ( Huang, RS; Marable, M; Rudin, S, 2017) |
| "Those drugs are the backbone of acute lymphoblastic leukemia (ALL) and several autoimmune disease treatments." | ( Bekker-Mendez, C; Del Carmen Pinto-Escalante, D; Del Carmen Rodríguez-Zepeda, M; Flores-Lujano, J; Flores-Villegas, LV; Fragoso, JM; García-Escalante, MG; González-Montalvo, PM; Guerra-Castillo, FX; Gutiérrez-Juárez, EI; Hidalgo-Miranda, A; Jiménez-Hernández, E; Jiménez-Morales, S; Leal, YA; Mejía-Aranguré, JM; Núñez-Enríquez, JC; Núñez-Villegas, NN; Pantoja-Guillen, F; Peñaloza-Gonzalez, JG; Pérez-Saldivar, ML; Ramírez-Bello, J; Ramírez-Florencio, M; Ramos-Cervantes, MT; Torres-Escalante, JL, 2016) |
| "Herein, we report a patient with acute lymphoblastic leukemia that experienced acute liver injury following pegaspargase administration." | ( Baker, WJ; Blackman, A; Boutin, A; Forcello, N; Shimanovsky, A, 2018) |
| "In childhood acute lymphoblastic leukemia, treatment failure is associated with resistance to glucocorticoid agents." | ( Arcaro, A; Ćwiek, P; Dimitrova, V; Dulcey, AS; Leibundgut, K; Leni, Z; Rossi, G; Simillion, C; Zamboni, N, 2017) |
| "Childhood acute lymphoblastic leukemia (ALL), being the most common malignancy in childhood, which is treated with uniform and standardized clinical trials, is remarkably poised for pharmacogenomic studies." | ( Lee, SHR; Yang, JJ, 2017) |
| "capitatus peritonitis in child with acute lymphocytic leukemia as a breakthrough infection during caspofungin therapy." | ( Aktaş, E; Bariş, A; Dalgiç, N; Gencer, H; Özakkaş, F; Şik, G, 2017) |
| "Treatment of acute lymphoblastic leukemia requires high-dose systemic and/or intrathecal methotrexate to prevent and/or treat central nervous system disorders." | ( Akbaraly, T; Deneux, V; Haouy, S; Leboucq, N; Saumet, L; Sirvent, N, 2017) |
| "Treatment of acute lymphoblastic leukemia (ALL) fails in some cases and the side effects cause mortality in certain patients." | ( Pourgheysari, B; Shirzad, H; Shirzad, M; Sourani, Z, 2017) |
| "Acute lymphoblastic leukemia is an invasive malignancy which ought to be treated with several cytotoxic medications." | ( Ghavamzadeh, A; Hadjibabaie, M; Khajeh, B; Masoumi, HT; Zarif-Yeganeh, M, 2019) |
| "Survivors of childhood acute lymphoblastic leukemia (ALL) are at risk of late treatment-related side-effects." | ( Christensen, JR; Edvardsen, E; Kanellopoulos, A; Kongerud, J; Lund, MB; Myrdal, OH; Ruud, E; Sikkeland, LI, 2018) |
| "Eighty percent of children with acute lymphoblastic leukemia (ALL) survive with current treatments." | ( Felice, MS; Guitter, MR; Millan, NC; Monges, MS; Pastrana, A; Zubizarreta, PA, 2018) |
| "Rarely seen in acute lymphoblastic leukemia, we report 2 patients who presented with normal coagulation markers, but subsequently developed severe hypofibrinogenemia and bleeding in induction before administration of asparaginase." | ( Felker, J; Lew, G; Patel, KN; Raikar, SS; Sidonio, RF, 2018) |
| "Although childhood acute lymphoblastic leukemia (ALL) is characterized by high remission rates, there are still patients who experience poor response to therapy or toxic effects due to intensive treatment." | ( Avgeris, M; Baka, M; Drakaki, I; Gourgiotis, D; Kossiva, L; Marmarinos, A; Piatopoulou, D; Pourtsidis, A; Scorilas, A; Xagorari, M, 2018) |
| "Methotrexate (MTX) is a key component of acute lymphoblastic leukemia (ALL) therapy, but it is associated with serious toxicities in a considerable number of patients." | ( Elloumi, M; Frikha, R; Ghozzi, H; Hakim, A; Mahmoud, LB; Mdhaffar, M; Sahnoun, Z; Zeghal, K, 2018) |
| "Chemotherapeutic agents used to treat acute lymphoblastic leukemia (ALL), the most common cancer affecting young children, have been associated with long-term cognitive impairments that reduce quality of life." | ( Cheung, YT; Glass, JO; Hudson, MM; Kesler, SR; Krull, KR; Ogg, R; Phillips, N; Pui, CH; Reddick, WE; Robison, LL; Scoggins, M, 2018) |
| "A 32-year-old woman who suffered from acute lymphoblastic leukemia was admitted and received treatment with vincristine and dexamethasone." | ( Ghavamzadeh, A; Gholami, K; Hadjibabaie, M; Taghvaye Masoumi, H; Zarif-Yeganeh, M, 2019) |
| "Pediatric patients with lymphoblastic lymphoma are generally treated using the Berlin-Frankfurt-Munster (BFM) 90 protocol, which is the standard treatment strategy for pediatric acute lymphoblastic leukemia, and have a favorable outcome." | ( Fujimoto, J; Horibe, K; Sekimizu, M; Sunami, S; Takimoto, T; Tsurusawa, M, 2018) |
| "In acute lymphoblastic leukemia (ALL), high ABCB1 gene expression has been associated with treatment resistance, which affects patient prognosis." | ( Cerón-Maldonado, R; Collazo-Jaloma, J; Kassack-Ipiña, JJ; Martínez-Tovar, A; Meléndez-Mier, G; Olarte-Carrillo, I; Ramos-Peñafiel, C; Rozen-Fuller, E, 2018) |
| "Acute lymphoblastic leukemia (ALL) and its treatment are associated with endothelial dysfunction (ED) and increased cardiovascular risk in adulthood." | ( Huml, M; Jehlička, P; Kreslová, M; Masopustová, A; Sýkora, J; Trefil, L; Votava, T, 2018) |
| "Although cure rates in pediatric acute lymphoblastic leukemia (ALL) are quite high with combined chemotherapy regimens, complete response (CR) and long-term survival rates in adults are 80-90 and 30-40%, respectively." | ( Akidan, O; Erkut, N; Karabacak, V; Selim Batur, D; Sonmez, M, 2018) |
| "The treatment of relapsed/refractory acute lymphoblastic leukemia (RR-ALL) presents a true clinical challenge." | ( Gatt, ME; Gural, A; Nachmias, B; Shapira, M; Shaulov, A, 2018) |
| "Acute lymphoblastic leukemia is the most common malignancy in childhood and requires prolonged oral maintenance chemotherapy to prevent disease relapse after remission induction with intensive intravenous chemotherapy." | ( Jost, F; Le, TTT; Metzler, M; Rauh, M; Raupach, T; Sager, S; Stanulla, M; Suttorp, M; Zierk, J, 2019) |
| "He had been successfully treated for acute lymphoblastic leukemia (ALL), at 3 years of age, with chemotherapy that included a cumulative dose of cyclophosphamide of 15." | ( Azuma, E; Hirayama, M; Ito, T; Iwamoto, S; Koyama, S, 2018) |
| "The poor outcomes in infant acute lymphoblastic leukemia (ALL) necessitate new treatments." | ( Barrett, JS; Borden, KLB; Carroll, AJ; Carroll, MP; Chen, IL; Culjkovic-Kraljacic, B; Davenport, JW; Devidas, M; Dreyer, ZE; Felix, CA; Harvey, RC; Heerema, NA; Hilden, JM; Hunger, SP; Jin, S; Moore, JS; Porazzi, P; Robinson, BW; Seif, AE; Tasian, SK; Teachey, DT; Urtishak, KA; Vincent, TL; Wang, LS; Willman, CL, 2019) |
| "We report a case of a patient with acute lymphoblastic leukemia (ALL), who developed a disseminated infection by Fusarium verticillioides during chemotherapy-induced neutropenia." | ( Díaz, MC; Luppi, M; Olivares, R, 2018) |
| "Acute lymphoblastic leukemia (ALL) is one of the most frequent malignancies in childhood whose long-term survival has increased up to 80% thanks to modern therapy enhancements." | ( Barrea, C; Forget, P; Geurten, C; Hoyoux, C; Leroy, P, 2020) |
| "Infants with acute lymphoblastic leukemia (ALL) treated with high-dose methotrexate may have reduced methotrexate clearance (CL) due to renal immaturity, which may predispose them to toxicity." | ( Beechinor, RJ; Bomgaars, LR; Dreyer, ZE; Gerhart, JG; Gonzalez, D; Hwang, MF; Thompson, PA; Vargo, RC, 2019) |
| "Acute lymphoblastic leukemia (ALL) with BCR-ABL1 translocation is an aggressive malignancy that is usually treated with intensive chemotherapy with the possibility of allogeneic stem cell transplantation." | ( Brattås, MK; Bruserud, Ø; Reikvam, H; Tvedt, THA, 2019) |
| "The mean FPGS activity of acute lymphoblastic leukemia blast cells (n = 4) was 3-fold higher than that of CCRF-CEM cells and 44-fold and 88-fold higher than that of peripheral blood mononuclear cells from MTX-naive (n = 9) and MTX-treated RA patients (n = 6), respectively." | ( Cloos, J; de Jonge, R; Hebing, RCF; Heydari, P; Jansen, G; Lems, WF; Lin, M; Muller, IB; Nurmohamed, MT; Struys, EA; van der Laken, C, 2019) |
| "Combination therapy for acute lymphoblastic leukemia (ALL) is highly effective but results in significant toxicity including osteonecrosis." | ( Cai, X; Evans, WE; Janke, LJ; Jenkins, DA; Karol, SE; Panetta, JC; Payton, MA; Ramsey, LB; Relling, MV, 2019) |
| "We report three cases of acute lymphoblastic leukemia (ALL) those were suffered from cytomegalovirus retinitis (CMVR) during maintenance phase therapy." | ( Begum, F; Begum, M; Kibria, CH; Rahman, AA; Shah, MS, 2019) |
| "Drug-resistant acute lymphoblastic leukemia (ALL) patients do not respond to standard chemotherapy, and an urgent need exists to develop new treatment strategies." | ( Asthana, A; Beck, R; Gram, H; Letterio, J; Parameswaran, R; Vicioso, Y; Wong, DP; Zhang, K, 2019) |
| "Recent data on acute lymphoblastic leukemia (ALL) treatment with multi-agent chemotherapy showed excellent response in pediatric patients in terms of long-term survival; however, the clinical needs for adult patients are still unmet." | ( Chai-Adisaksopha, C; Norasetthada, L; Rattanathammethee, T; Rattarittamrong, E; Tantiworawit, A, 2019) |
| "The standard treatment for adult acute lymphoblastic leukemia (ALL) is undefined." | ( Cai, X; Chen, X; Li, C; Liang, Y; Wang, H; Xia, Z, 2019) |
| "Treatment of acute lymphoblastic leukemia (ALL) in adolescent and young adult (AYA) patients using traditional adult chemotherapy protocols give low overall survival (OS) rates." | ( Ahmed, SO; Alahmari, A; Alfraih, F; Alhayli, S; Aljurf, M; Almohareb, F; Alsharif, F; Alzahrani, H; Chaudhri, N; El Fakih, R; Hanbali, A; Hashmi, S; Kotb, A; Rasheed, W; Riash, MA; Shaheen, M, 2019) |
| "Survivors of childhood acute lymphoblastic leukemia (ALL) treated with chemotherapy only are at risk for neurocognitive impairment." | ( Cheung, YT; Glass, JO; Hudson, MM; Krull, KR; Liu, W; Mulrooney, DA; Ogg, RJ; Phillips, NS; Pui, CH; Reddick, WE; Robison, LL; Scoggins, MA, 2020) |
| "Glucocorticoids used to treat acute lymphoblastic leukemia (ALL) are associated with cytotoxicity and obesity." | ( Chen, J; Huang, H; Jiang, H; Li, Y; Liang, Z; Sun, J; Zhang, R; Zheng, H, 2019) |
| "The incidence of Acute Lymphoblastic Leukemia (ALL) is increasing globally, and it is being clinically addressed by chemotherapy, followed by immunotherapy and stem cell transplantation, all with potential life-threatening toxicities." | ( Astilean, S; Berindan-Neagoe, I; Boca, S; Cialla-May, D; Florea, A; Jurj, A; Popp, J; Tatar, AS; Tomuleasa, C, 2019) |
| "Treatment outcomes for childhood acute lymphoblastic leukemia (ALL) have improved steadily, but a significant proportion of patients still experience relapse due to drug resistance, which is partly explained by inherited and/or somatic genetic alternations." | ( Bhojwani, D; Carroll, WL; E, S; Evans, WE; Goodings, C; Li, C; Seibel, NL; Xu, H; Yang, JJ; Yang, W; Zhang, H; Zhao, X, 2020) |
| "In childhood acute lymphoblastic leukemia, high treatment-related mortality, especially in the induction phase of treatment, is a major challenge for developing countries." | ( Ashraf, S; Butt, Z; Jabbar, N; Mansoor, N; Maqsood MSc, S; Nadeem, K, 2020) |
| "Acute lymphoblastic leukemia (ALL) develops in the bone marrow in the vicinity of stromal cells known to promote tumor development and treatment resistance." | ( Bhagwat, S; Blomhoff, HK; Burman, MM; Duthil, E; Ford, A; Gilljam, KM; Naderi, EH; Richartz, N; Ruud, E; Skah, S, 2019) |
| "The treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in children is challenging and new treatment options are needed." | ( August, KJ; Gamis, AS; Guest, EM; Hays, JA; Lewing, K, 2020) |
| "Acute lymphoblastic leukemia maintenance chemotherapy includes mercaptopurine, a purine analog with uncommon side effects, that can be life-threatening." | ( Oliveira, J; Rebelo, A; Sousa, C, 2020) |
| "Children with acute lymphoblastic leukemia submitted to chemotherapy, present auditory pathway impairment in the brainstem, with a predominance of a low brainstem." | ( Cortez Neto, L; Leite, RA; Matas, CG; Matas, SLA; Odone Filho, V; Santos, NP; Vosgrau, JS, 2020) |
| "Pediatric patients with acute lymphoblastic leukemia and lymphoblastic lymphoma are prescribed a daily oral chemotherapy medication named 6-mercaptopurine." | ( Ewing, LJ; Isaac, EI; Katz, ER; Meisman, AR; Muriel, AC; Rohan, JM; Sivagnanalingam, U; Wetherington Donewar, C, 2020) |
| "Acute lymphoblastic leukemia (ALL) is curable with standardized chemotherapy." | ( Goto, H; Goto, S; Hamanoue, S; Inukai, T; Ito, M; Iwasaki, F; Keino, D; Kumamoto, T; Miyagawa, N; Nagai, J; Sakurai, Y; Shiomi, M; Yokosuka, T; Yoshino, Y, 2020) |
| "Patients undergoing treatment of acute lymphoblastic leukemia (ALL) are at risk for thrombosis, caused in part by the use of l-asparaginase (L-ASP)." | ( Balsat, M; Boissel, N; Bonmati, C; Cacheux, V; Caillot, D; Chalandon, Y; Chantepie, S; Chevallier, P; de Gunzburg, N; Dombret, H; Frayfer, J; Huguet, F; Hunault-Berger, M; Ifrah, N; Lheritier, V; Marolleau, JP; Orvain, C; Pabst, T; Tavernier, E, 2020) |
| "High-risk B-cell acute lymphoblastic leukemia (B-ALL) is an aggressive disease, often characterized by resistance to chemotherapy." | ( Amin, S; Cury, NM; Desai, D; Dhanyamraju, PK; Ding, Y; Dovat, S; Ge, Z; Gowda, C; Gowda, K; Gowda, R; Gurel, Z; Huang, S; Iyer, S; Kawasawa, YI; Lyu, X; McGrath, M; Muschen, M; Payne, JL; Payne, KJ; Reeves, ME; Robertson, GP; Schramm, J; Song, C; Spiegelman, V; Su, R; Tan, BH; Xiang, M; Yang, Y; Yue, F; Yunes, JA; Zhao, Z, 2020) |
| "Improved survival of childhood acute lymphoblastic leukemia (ALL) has diverted attention to the long-term consequences of the treatment; metabolic abnormalities being one of the most important issues." | ( Chellapam Sojamani, G; Krishna K M, J; Nair, M; Nirmal, G; Rajeswari, B; Thankamony, P; Varikkattu Rajendran, P, 2021) |
| "Recent clinical trials in children with acute lymphoblastic leukemia (ALL) indicate that severe hypertriglyceridemia (> 1000 mg/dL) during therapy is associated with increased frequency of symptomatic osteonecrosis." | ( Cai, X; Finch, ER; Janke, LJ; Jenkins, DA; Karol, SE; Li, L; Payton, MA; Relling, MV, 2021) |
| "Methotrexate (MTX) is a key drug in acute lymphoblastic leukemia (ALL) treatment; it inhibits DNA replication by blocking the conversion of 5, 10 Methylenetetrahydrofolate to 5-methylene tetrahydrofolate by methylenetetrahydrofolate reductase (MTHFR)." | ( Elloumi, M; Frikha, F; Frikha, R; Jemaa, MB; Kamoun, H; Keskes, L; Rebai, T; Turki, I, 2021) |
| "Children with acute lymphoblastic leukemia (ALL) suffer from a litany of chemotherapy-induced side effects." | ( Belsky, JA; O'Brien, SH; Stanek, JR, 2020) |
| "acute lymphoblastic leukemia-type chemotherapy that incorporated high-dose cytarabine was effective in achieving an minimal residual disease-negativity rate of 69% in evaluated patients, which was also predictive of better outcome." | ( Banavali, S; Gujral, S; Myint, HH; Narula, G; Patkar, N; Prasad, M; Subramanian, P; Tandon, S; Tembhare, P, 2020) |
| "Adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) are more likely to have chemotherapy-related complications than children." | ( Hori, D; Kobayashi, K; Kobayashi, R; Kodama, K; Matsushima, S; Sano, H; Suzuki, D; Yanagi, M, 2021) |
| "Participants included survivors of childhood ALL who were more than 5 years from cancer diagnosis, age 8 years or older, and treated on an institutional chemotherapy-only protocol." | ( Banerjee, P; Cheung, YT; Glass, JO; Hudson, MM; Kesler, SR; Krull, KR; Liu, W; Ogg, RJ; Phillips, NS; Pui, CH; Reddick, WE; Robison, LL; Scoggins, MA; Srivastava, D, 2020) |
| "Current treatment of pediatric acute lymphoblastic leukemia allows survival above 80%, but it is also very important to prevent treatment-related side effects and to improve long-term quality of life." | ( Beniczky, NJ; Erdélyi, DJ; Hosszú, É; Jakab, Z; Kovács, G; Müller, J, 2020) |
| "A 3-year-old boy with B-cell precursor acute lymphoblastic leukemia who was administered thiopurine developed mucositis, sepsis, and hemophagocytic lymphohistiocytosis due to prolonged hematologic toxicity, chronic disseminated candidiasis, and infective endocarditis that triggered multiple brain infarctions." | ( Ito, E; Kamio, T; Kato, M; Kobayashi, A; Kudo, K; Otani, K; Sasaki, S; Sato, T; Shimada, J; Takahashi, Y; Terui, K; Toki, T; Tusjimoto, S; Yuzawa, K, 2021) |
| "Current treatment protocols in acute lymphoblastic leukemia (ALL) are associated with high remission rates and long life expectancy, enhancing the importance of quality of life and prevention of treatment-related complications in patient care." | ( Abdurrezzak, U; Karakukcu, M; Muhtaroglu, S; Ozdemir, MA; Solmaz, I; Unal, E, 2021) |
| "Mercaptopurine (6MP) is used to treat acute lymphoblastic leukemia (ALL) and is metabolized by hypoxanthine guanine phosphoribosal transferase to form 6-thioguanine nucleotide (6TGN)." | ( Bostrom, B; Kamojjala, R, 2021) |
| "However, the very specific nature of acute lymphoblastic leukemias and their treatment in children and adolescents led the Leukemia Committee of the French Society for the fight against Cancers and leukemias in children and adolescents (SFCE) to propose more specific recommendations." | ( Baruchel, A; Bertrand, Y; Boissel, N; Brethon, B; Ducassou, S; Gandemer, V; Halfon-Domenech, C; Leblanc, T; Leverger, G; Michel, G; Petit, A; Ray-Lunven, AF; Rohrlich, PS; Rouger-Gaudichon, J; Schneider, P; Sirvent, N; Strullu, M, 2021) |
| "In Philadelphia chromosome-positive acute lymphoblastic leukemia with BMN, tyrosine kinase inhibitor replacement may allow continued chemotherapy without intensity reduction." | ( Adachi, S; Hiramatsu, H; Kamitori, T; Kato, I; Mikami, T; Ogata, H; Oiki, N; Okamoto, S; Okamoto, T; Takita, J; Tanaka, K; Tasaka, K; Umeda, K, 2022) |
| "Therapy for childhood acute lymphoblastic leukemia (ALL) is associated with substantial health care utilization and burden on families." | ( Athale, U; Bassal, M; Breakey, VR; Gibson, PJ; Gupta, S; Li, Q; Mittmann, N; Patel, S; Pechlivanoglou, P; Pole, JD; Silva, M; Sutradhar, R; Zabih, V, 2021) |
| "Treatment of pediatric acute lymphoblastic leukemia (ALL) with pegaspargase exploits ALL cells dependency on asparagine." | ( Bielawski, JP; Cohen, A; Connors, J; Dunn, KA; Forbrigger, Z; Kulkarni, K; Langille, MGI; MacDonald, T; Penny, SL; Rahman, M; Stadnyk, AW; Van Limbergen, J, 2021) |
| "They are used to treat acute lymphoblastic leukemia and Hodgkin's lymphomas and in food industries." | ( Abdel-Fattah, M; Ataya, FS; El-Nikhely, N; Eldoksh, A; Elkewedi, M; Elsawy, E; Hemida, A; Labrou, NN; Nematalla, H; Saeed, H; Shalaby, M, 2022) |
| "Children with acute lymphoblastic leukemia (ALL) often experience treatment-related neurocognitive deficits and significant pain." | ( Alberts, NM; Anghelescu, DA; Conklin, HM; Jacola, LM; Krull, KR; Partanen, M; Pui, CH, 2022) |
| "Unlike younger adults with acute lymphoblastic leukemia (ALL), older adults are rarely cured due to a combination of intrinsic disease resistance and treatment-related toxicities." | ( Luskin, MR, 2021) |
| "Before acute lymphoblastic leukemia drug treatment, the metabolic parameters (glucose, insulin, homeostasis model assessment insulin resistance, total cholesterol, triglycerides) and body mass index percentile were compared." | ( Ávila-Castro, D; Chávez-Aguilar, LA; Merino-Pasaye, LE; Peña-Vélez, R, 2022) |
| "The treatment of acute lymphoblastic leukemia (ALL) is one of the success stories of pediatric oncology, but challenges and questions remain, including the optimal approach to the treatment of central nervous system (CNS) leukemia." | ( McNeer, JL; Schmiegelow, K, 2022) |
| "Optimal conditioning for adults with acute lymphoblastic leukemia (ALL) treated with haploidentical hematopoietic cell transplantation (haplo-HCT) and post-transplant cyclophosphamide has not been established so far." | ( Aljurf, M; Angelucci, E; Arat, M; Bernasconi, P; Giebel, S; Labopin, M; Mohty, M; Nagler, A; Pavlu, J; Peric, Z; Pioltelli, P; Rigacci, L; Risitano, A; Rovira, M; Saccardi, R; Savani, BN; Sica, S; Socié, G; Spyridonidis, A; Swoboda, R; Tischer, J; Van Gorkom, G; Vitek, A, 2022) |
| "Ten acute lymphoblastic leukemia (ALL) and 1 lymphoma patient 8 to 18 years of age who completed treatment 6 to 36 months prior and 11 healthy controls participated in the study." | ( Caterini, JE; Jones, H; Nathan, PC; Rayner, T; Rhind, SG; Sabiston, C; Weiss, R; Wells, GD; West, SL; White, GE, 2022) |
| "Pediatric acute lymphoblastic leukemia (pALL) patients have better overall survival and methotrexate (MTX) is an effective drug used in their treatment." | ( Arunkumar, G; Kaur, H; Paul, SFD; Ramalingam, R; Scott, JX; Sneha, LM; Srinivasan, A, 2022) |
| "Pediatric B-cell lymphoblastic lymphoma (LBL) is a rare entity, and appropriate treatment for pediatric B-cell LBL is not well defined." | ( Banavali, SD; Dhamne, C; Gujral, S; Kc, A; Kembhavi, S; Laskar, S; Narula, G; Prasad, M; Roy Moulik, N; Shah, S; Shet, T; Sridhar, E; Vijayasekharan, K, 2022) |
| "6-mercaptopurine is a mainstay of acute lymphoblastic leukemia treatment." | ( Alexander, TB; Geib, KB; Gold, S; Newcome, J; Thompson, P, 2022) |
| "Childhood acute lymphoblastic leukemia (ALL) fortunately has high survival rates, and understanding longer term implications of therapy is critical." | ( Kumar, R; Mahan, JD; Reed, S; Stanek, JR, 2022) |
| "In spite of the great progress in acute lymphoblastic leukemia (ALL) treatment, a large number of patients still suffer from chemotherapy drug toxicity." | ( Anani-Sarab, G; Rastgar, A; Sajjadi, SM; Sayadi, M, 2022) |
| "Outcomes in patients diagnosed of acute lymphoblastic leukemia with Philadelphia chromosome (Ph-ALL) remains unfavourable compared to other subtypes of acute lymphoblastic leukemia despite improvements in drug treatments as well as advances in hematopoietic stem cell transplantation (HSCT)." | ( Badell Serra, I; de la Fuente Regaño, L; Díaz de Heredia Rubio, C; Galán Gómez, V; González Vicent, M; Isabel Pascual Martínez, A; López Duarte, M; María Fernández, J; María Pérez Hurtado, J; Pérez-Martínez, A; Rodríguez Villa, A; Soledad Maldonado Regalado, M, 2022) |
| "Children with B-acute lymphoblastic leukemia (B-ALL) are at risk for chemotherapy-induced peripheral neuropathy (CIPN)." | ( Angiolillo, AL; Devidas, M; Hibbitts, E; Hockenberry, MJ; Hunger, SP; Kadan-Lottick, NS; Kairalla, JA; Loh, ML; Mohrmann, CE; Ness, KK; Raetz, E; Rodwin, RL; Schore, RJ; Whitley, MK; Winick, NJ, 2022) |
| "Acute lymphoblastic leukemia (ALL) is the most common malignancy in children and relapsed B-ALL is the leading cause of mortality in children with leukemia due to a lack of response to treatment." | ( Hejazi, MJ; Kohan, N; Sharifi, M; Tamaddon, G, 2022) |
| "Although acute lymphoblastic leukemia (ALL) is highly responsive to chemotherapy, it is unknown how or which host immune factors influence the long-term remission of this cancer." | ( Cheng, C; Chi, H; Easton, J; Ju, B; Lee, S; Li, Y; Li, Z; Pei, D; Pui, CH; Sun, Y; Yang, JJ; Yang, W; Yang, X; Yu, J, 2022) |
| "Methotrexate is the backbone of acute lymphoblastic leukemia treatment, but numerous adverse reactions have been published of which methotrexate pneumonitis can be fatal in some cases." | ( Boufrikha, W; Boukhriss, S; Cheffaï, A; Laatiri, MA; Rakez, R, 2023) |
| "While outcomes for children with T-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LL) have improved significantly with contemporary therapy, outcomes for patients with relapsed or refractory (r/r) disease remain dismal." | ( Summers, RJ; Teachey, DT, 2022) |
| "Besides, the PLK4 expression in childhood ALL patients was also determined at day 15 after the initiation of induction therapy (D15)." | ( Xu, J; Zhao, L, 2023) |
| "Acute lymphoblastic leukemia (ALL) with recurrent genetic lesions, affecting a series of kinase genes, is associated with unfavorable prognosis, however, it could benefit from treatment with tyrosine kinase inhibitors (TKI)." | ( Dirse, V; Norvilas, R; Stankeviciene, S; Stukaite-Ruibiene, E; Vaitkeviciene, GE, 2022) |
| "Acute lymphoblastic leukemia (ALL) represents one of the major cancers affecting children, and although substantial progress has been made in its treatment, relapses are frequent after initial treatment and are now one of the leading causes of cancer-related death in pediatric patients." | ( Lagunas-Rangel, FA; Liu, W; Schiöth, HB, 2023) |
| "Patients age ≥55 years with acute lymphoblastic leukemia (ALL) fare poorly with conventional chemotherapy, with a 5-year overall survival (OS) of ∼20%." | ( Ali, SA; Ambinder, A; Ambinder, RF; Bolanos-Meade, J; Borrello, IM; Dalton, WB; Dezern, AE; Fuchs, EJ; Ghiaur, G; Gladstone, DE; Gocke, CB; Gojo, I; Gondek, LP; Hourigan, CS; Huff, CA; Imus, PH; Jain, T; Jones, RJ; Levis, MJ; Luznik, L; Paul, S; Prince, GT; Reed, M; Showel, MM; Smith, BD; Swinnen, L; Tsai, HL; Varadhan, R; Wagner-Johnston, N; Webster, JA, 2023) |
| "Hypodiploid acute lymphoblastic leukemia (ALL) is an aggressive blood cancer with a poor prognosis despite intensive chemotherapy or stem cell transplant." | ( Ang, KK; Arkin, MR; Bachl, S; Beckman, K; Braun, BS; Diaz-Flores, E; Fandel, J; Loh, ML; Markossian, S; Olshen, AB; Pariury, H; Popescu, B; Roy, RP; Smith, C; Wilson, CG; Wohlfeil, M; Xirenayi, S, 2023) |
| "The prognosis of B-cell acute lymphoblastic leukemia (B-ALL) has improved significantly with current first-line therapy, although the recurrence of B-ALL is still a problem." | ( Bai, L; Chen, J; Chen, Y; Cui, J; Gu, X; Han, W; Hu, Z; Li, H; Li, W; Niu, C; Yang, Y; Zhang, X; Zhou, L, 2023) |
| "As a mainstay of treatment for acute lymphoblastic leukemia (ALL), vincristine's side effect profile is well known." | ( Beck, J; Cave, C; Ford, J; High, R; Ramirez, R; Raulji, C, 2023) |
| "l-Asparaginase is a cornerstone of acute lymphoblastic leukemia (ALL) therapy since lymphoblasts lack asparagine synthetase (ASNS) and rely on extracellular asparagine availability for survival." | ( Aguera, K; Andrivon, A; Blachier, J; Châlons-Cottavoz, M; Cleret, A; Fanjat, JM; Gallix, F; Gay, F; Gil, C; Guerin, N; Horand, F; Laperrousaz, B; Piedrahita, D; Rama, N; Rossignol, R; Tavernier, F; Vidault, L, 2023) |
| "Treatment of acute lymphoblastic leukemia (ALL) requires both systemically and locally directed therapies to prevent central nervous system (CNS) recurrence." | ( Chan, A; Ciurea, SO; Doh, J; Griffin, SP; Jeyakumar, D; Kongtim, P; Lee, BJ; O'Brien, S, 2023) |
| "Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a high-risk subtype with a poor prognosis under conventional chemotherapy." | ( Cao, HY; Dai, HP; Huang, SM; Li, YY; Qiu, QC; Shen, HJ; Tan, KW; Wan, CL; Wang, M; Xue, SL; Zhu, YY, 2023) |
| "Children with acute lymphoblastic leukemia (ALL) are treated with doxorubicin-based chemotherapy that can lead to cardiotoxicity which is a well-known cause of mortality." | ( Abasq, M; Artz, T; Caru, M; Curnier, D; Krajinovic, M; Laverdière, C; Périé, D; Sinnett, D, 2023) |
| "The maintenance phase of acute lymphoblastic leukemia treatment is the final and longest stage of treatment, mainly focused on antimetabolite therapy." | ( Abula, T; Adam, H; Ali, AM; Coenen, MJH; Hailu, D; Howe, R, 2023) |
| "In the treatment of childhood acute lymphoblastic leukemia (ALL), current protocols combine initial high-dose multiagent chemotherapy with prolonged oral therapy with 6-mercaptopurine (6MP) and low-dose methotrexate (MTX) maintenance therapy." | ( Gebhard, A; Lilienthal, P; Metzler, M; Rauh, M; Sager, S; Schmiegelow, K; Toksvang, LN; Zierk, J, 2023) |